

報 告

婦人科腫瘍委員会

第56回治療年報

2008年に治療した子宮頸癌，子宮体癌，卵巣悪性・境界悪性腫瘍の5年治療成績について

婦人科腫瘍委員会の第56回治療年報(2008年治療開始例)の報告をいたします。

予後の解析は例年通り，Kaplan-Meier法を用いております。追跡不能症例(Lost to follow-up)が多いと治療成績の信頼性が低下するため，予後追跡報告で追跡不能症例が20%を超える施設のデータは治療成績の解析には用いないこととしています。予後解析に使用された施設は，施設名に左に○がつけてあります。

また，従来は治療年報のデータにつきましては疑義照会を行っておりませんでした，データの品質向上を目的として，第56回治療年報よりデータマネージメントのシステムを見直し，疑義照会をプログラム化したうえで，複数回の疑義照会を実施いたしました。

腫瘍登録に参加していただいた加盟機関の先生方の多大なご尽力に感謝申し上げます，また婦人科腫瘍委員会の全委員およびデータセンターに御礼申し上げます。今後とも患者年報・治療年報のさらなる充実を目指してまいりますので，ご協力賜りますようお願い申し上げます。

平成25～26年度 婦人科腫瘍委員会 委員長 青木 大輔

子宮頸癌治療成績

Table A 5年後の治療転帰

Table 1-8 項目別成績

Figure 1-10 予後5年全生存率

子宮体癌治療成績

Table A 5年後の治療転帰

Table 1-8 項目別成績

Figure 1-10 予後5年全生存率

卵巣悪性腫瘍治療成績

Table A 5年後の治療転帰

Table 1-8 項目別成績

Figure 1-12 予後5年全生存率

卵巣境界悪性腫瘍治療成績

Table A 5年後の治療転帰

Table 1-7 項目別成績

Figure 1 予後5年全生存率

また、下記の項目については、第55回より記載方法を一部変更しております。ご注意ください。

- 1)各癌の組織型の内訳を表にまとめ、記載しました。(子宮頸癌 Table 3, 子宮体癌 Table 3, 卵巣悪性腫瘍 Table 2, 卵巣境界悪性腫瘍 Table 2)
- 2)子宮体癌の分化度については、類内膜腺癌のみ分類することとしました。
(子宮体癌 Table 3, 6, 7)
- 3)子宮体癌は分化度別の生存曲線を記載しておりましたが、今回より組織型別の生存曲線を記載することとしました。(子宮体癌 Figure 2, 4, 6, 8, 10)
- 4)卵巣悪性腫瘍についても、進行期別の組織型別生存曲線を記載しました。
(卵巣悪性腫瘍 Figure 4, 6, 8)
- 5)卵巣境界悪性腫瘍についても、生存曲線を記載しました。
(卵巣境界悪性腫瘍 Figure 1)

本報告に関するお問い合わせは婦人科腫瘍委員会にお願いいたします。

子宮頸癌治療成績

Statement for the Year 2008, Inclusive, Cervix

Table A. 5-Year Results, Stage I-IV

	A	B	C	D	E	F	G	H	I	J	K	
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up	
○	010003	HOKKAIDO CANCER CENTER	34	0	23	0	0	10	0	0	0	1
	010024	NTT EAST JAPAN SAPPORO HOSP.	5	0	1	0	0	0	0	0	0	4
○	010025	SAPPORO MED. UNIV.	50	0	44	0	0	4	0	0	0	2
○	010027	HOKKAIDO UNIV.	17	0	12	0	0	5	0	0	0	0
○	010028	KKR SAPPORO MED. CENTER	10	0	8	0	0	2	0	0	0	0
	010037	ASAHIKAWA-KOSEI GENERAL HOSP.	3	3	0	0	0	0	0	0	0	0
	010038	ASAHIKAWA MED. UNIV.	18	0	11	0	0	2	0	0	0	5
○	010040	ASAHIKAWA MED. COLL.	13	0	11	0	0	1	0	0	0	1
	020004	AOMORI PREF. CENTRAL HOSP.	12	12	0	0	0	0	0	0	0	0
○	020008	MUTSU GENERAL HOSP.	1	0	0	1	0	0	0	0	0	0
○	020012	HIROSAKI UNIV.	18	0	16	0	0	2	0	0	0	0
	020017	MISAWA CITY HOSP.	3	0	1	0	0	1	0	0	0	1
	030004	IWATE MED. UNIV.	1	1	0	0	0	0	0	0	0	0
	040004	TOHOKU UNIV.	44	0	18	1	0	12	0	2	0	11
○	040008	MIYAGI CANCER CENTER	18	0	14	0	0	3	0	0	1	0
	040013	SENDAI MED. CENTER	15	12	0	0	0	3	0	0	0	0
○	050001	AKITA RED CROSS HOSP.	4	0	0	0	0	4	0	0	0	0
	050003	AKITA UNIV.	32	0	20	0	0	4	0	0	0	8
○	060002	YAMAGATA PREF. CENTRAL HOSP.	19	0	13	0	0	3	0	1	0	2
	060005	YAMAGATA UNIV.	26	1	11	1	0	6	0	1	0	6
○	080001	TSUCHIURA KYODO GENERAL HOSP	17	0	13	1	0	2	0	0	0	1
○	080007	TSUKUBA UNIV.	74	3	53	1	0	11	0	0	1	5
	080021	HITACHI GENERAL HOSP.	15	15	0	0	0	0	0	0	0	0
	080031	TSUKUBA MED. CENTER	4	0	3	0	0	0	0	0	0	1
○	090001	TOCHIGI MED. CENTER	1	0	1	0	0	0	0	0	0	0
○	090004	DOKKYO MED. UNIV.	23	0	15	0	0	5	0	0	0	3
○	090005	SAISEIKAI UTSUNOMIYA HOSP.	8	0	5	0	0	3	0	0	0	0
○	090011	ASHIKAGA RED CROSS HOSP.	18	0	9	2	0	6	0	1	0	0
○	090015	JICHI MED. UNIV.	64	0	43	3	0	8	0	1	0	9
○	090016	TOCHIGI CANCER CENTER	37	0	27	2	0	5	0	0	0	3
○	100012	GUNMA UNIV.	58	0	41	2	0	5	0	0	0	10
○	110008	SAITAMA MED. CENTER	7	0	6	0	0	1	0	0	0	0
○	110014	KOSHIGAYA MUNI. HOSP.	13	0	10	1	0	2	0	0	0	0
○	110023	SAITAMA NATIONAL HOSP.	10	0	10	0	0	0	0	0	0	0
	110027	NATIONAL DEFENSE MED. COLL.	28	28	0	0	0	0	0	0	0	0
○	110030	SAITAMA CANCER CENTER	90	0	65	1	0	19	0	3	2	0
	110055	SAITAMA INTERNATIONAL MED. CENTER	48	0	20	3	0	8	0	1	0	16
	120005	CHIBA UNIV.	50	0	27	1	0	7	0	3	0	12
	120009	NIPPON MED. SCH. CHIBA HOKUSOU HOSP.	23	23	0	0	0	0	0	0	0	0
	120012	MATSUDO CITY HOSP.	9	0	7	0	0	0	0	0	0	2
○	120015	TOKYO DENTAL COLL. ICHIKAWA GENERAL HOSP.	13	0	8	0	0	4	0	0	0	1
	120021	JIKEI UNIV. KASHIWA HOSP.	35	35	0	0	0	0	0	0	0	0
○	120023	JUNTENDO UNIV. URAYASU HOSP.	22	0	15	1	0	4	0	0	0	2
○	120025	TOHO UNIV. SAKURA MED. CENTER	7	0	5	0	0	1	0	0	0	1
	120029	ASAHI CENTRAL HOSP.	27	26	0	1	0	0	0	0	0	0
○	120035	KAMEDA MED. CENTER	30	0	19	0	0	6	1	0	0	4
○	120042	CHIBA CANCER CENTER	52	0	31	1	0	17	0	0	1	2
○	120043	NATIONAL INS. OF RADIOLOGICAL SCIENCES	43	0	17	0	0	18	0	3	0	5
○	130005	MITSUMI MEMORIAL HOSP.	10	0	6	1	0	3	0	0	0	0
○	130009	NATIONAL CANCER CENTER	69	0	44	0	0	12	1	1	1	10
	130013	JIKEI UNIV.	23	0	10	1	0	4	0	0	1	7
○	130023	JUNTENDO UNIV.	32	0	17	0	0	8	3	0	0	4
	130024	TOKYO MED. DENT. UNIV.	17	17	0	0	0	0	0	0	0	0
	130025	NIPPON MED. SCH.	14	0	4	0	0	5	0	0	0	5

	A	B	C	D	E	F	G	H	I	J	K	
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up	
○	130026	TOKYO UNIV.	38	0	26	0	0	8	1	0	0	3
○	130029	TOKYO WOMENS MED. UNIV. MED. CENTER EAST	10	0	7	0	0	3	0	0	0	0
	130034	JIKEI UNIV. KATSUSHIKA MED. CENTER	23	23	0	0	0	0	0	0	0	0
	130038	TOKYO METRO. BOKUTOH HOSP.	9	9	0	0	0	0	0	0	0	0
○	130044	NTT MED. CENTER TOKYO	5	0	3	0	0	0	0	1	0	1
	130046	SHOWA UNIV.	19	0	8	0	0	3	0	0	0	8
	130050	TOHO UNIV. OMORI MED. CENTER	7	0	4	0	0	1	0	0	0	2
○	130055	RED CROSS MED. CENTER	8	0	6	1	0	1	0	0	0	0
○	130061	TOKYO MED. CENTER	24	0	17	0	0	4	0	1	0	2
○	130063	KOSEI CENTRAL HOSP.	1	0	1	0	0	0	0	0	0	0
○	130064	TOHO UNIV. OHASHI MED. CENTER	15	0	11	1	0	3	0	0	0	0
	130074	TOKYO MED. UNIV.	25	0	7	0	0	5	0	0	0	13
○	130077	KEIO UNIV.	82	0	61	0	0	10	0	0	0	11
	130080	NATIONAL CENTER FOR GLOBAL HEALTH AND MED.	6	6	0	0	0	0	0	0	0	0
	130081	TOKYO WOMENS MED. HOSP.	20	0	12	0	0	3	0	0	0	5
	130085	KOSEI HOSP.	6	0	2	0	0	2	0	0	0	2
	130092	TEIKYO UNIV.	24	0	13	0	0	3	0	0	0	8
○	130095	NIHON UNIV.	20	0	12	0	0	7	0	0	0	1
○	130099	MUSASHINO RED CROSS HOSP.	24	0	17	0	0	4	0	0	0	3
	130100	KYORIN UNIV.	23	0	12	1	0	4	0	0	0	6
○	130102	TOKYO METRO. TAMA MED. CENTER	31	0	19	2	0	4	0	0	0	6
	130107	TACHIKAWA HOSP.	22	0	10	1	0	4	0	0	0	7
○	130112	MACHIDA MUNI. HOSP.	4	0	3	0	0	1	0	0	0	0
	130119	NIPPON MED. SCH. TAMA NAGAYAMA HOSP.	8	8	0	0	0	0	0	0	0	0
○	130122	TOKYO METRO. KOMAGOME HOSP.	32	0	13	3	0	10	0	1	1	4
	130124	KYOUNDO HOSP.	23	0	15	0	0	2	0	0	0	6
○	130125	CANCER INST. HOSP.	133	0	94	3	0	25	0	1	0	10
	130135	TAMA-NAMBU SHIIKI HOSP.	8	8	0	0	0	0	0	0	0	0
	130137	TOKAI UNIV. HACHIOJI HOSP.	4	4	0	0	0	0	0	0	0	0
	140006	NIPPON MED. SCH. MUSASHI KOSUGI HOSP.	13	0	9	0	0	1	0	0	0	3
○	140008	KANTO ROSAI HOSP.	3	0	2	0	0	1	0	0	0	0
○	140012	ST. MARIANNA UNIV.	41	0	25	3	0	12	0	0	0	1
	140016	YOKOHAMA ROSAI HOSP.	14	0	5	1	0	5	0	0	0	3
	140017	SHOWA UNIV. FUJIGAOKA HOSP.	22	0	12	0	0	4	0	1	0	5
	140020	KITASATO UNIV.	53	0	23	1	0	13	0	0	0	16
○	140029	YOKOHAMA CITY UNIV.	53	0	38	0	0	14	1	0	0	0
	140030	YOKOHAMA MINAMI KYOSAI HOSP.	5	0	2	0	0	1	0	0	0	2
○	140035	YOKOHAMA MUNI. CITIZENS HOSP.	14	0	11	0	0	1	0	0	0	2
	140044	SHONAN KAMAKURA GENERAL HOSP.	3	0	1	0	0	0	0	0	0	2
○	140055	TOKAI UNIV.	50	0	32	1	0	8	1	1	0	7
○	140059	KANAGAWA CANCER CENTER	80	0	58	2	0	18	0	1	1	0
○	140061	YOKOHAMA CITY UNIV. MED. CENTER	14	0	8	0	0	4	0	0	0	2
○	150002	YAMANASHI PREF. CENTRAL HOSP.	20	0	13	0	0	3	0	0	0	4
○	150006	UNIV. OF YAMANASHI	19	0	10	0	0	5	0	1	0	3
	160001	NAGANO RED CROSS HOSP.	16	0	4	0	0	4	0	1	0	7
○	160022	NAGANO MUNI. HOSP.	18	0	13	0	0	2	0	0	1	2
	170006	FUJI CITY GENERAL HOSP.	1	1	0	0	0	0	0	0	0	0
	170009	SHIZUOKA RENERAL HOSP.	44	0	19	1	0	10	0	2	0	12
	180001	NAGAOKA RED CROSS HOSP.	16	0	9	1	0	1	0	0	0	5
○	190001	TOYAMA UNIV.	11	0	8	0	0	3	0	0	0	0
○	190002	TOYAMA RED CROSS HOSP.	6	0	3	0	0	3	0	0	0	0
	190009	TAKAOKA CITY HOSP.	4	0	0	1	0	1	0	0	0	2
○	200001	KANAZAWA MED. UNIV.	6	0	6	0	0	0	0	0	0	0
○	200002	KANAZAWA MED. CENTER	8	0	8	0	0	0	0	0	0	0
○	200004	KANAZAWA UNIV.	25	0	20	1	0	4	0	0	0	0
○	210002	FUKUI PREF. HOSP.	11	0	5	1	0	2	0	1	0	2
○	210004	FUKUI RED CROSS UNIV.	9	0	5	0	0	4	0	0	0	0
○	220002	GIFU UNIV.	33	0	22	0	0	9	0	0	1	1
○	220006	OGAKI MUNI. HOSP.	20	0	12	0	0	3	0	0	0	5

	A	B	C	D	E	F	G	H	I	J	K	
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up	
○	230001	TOYOHASHI MUNI. HOSP.	34	0	22	0	0	11	0	1	0	0
○	230014	RED CROSS NAGOYA DAIICHI HOSP.	21	0	15	1	0	5	0	0	0	0
○	230031	NAGOYA UNIV.	42	0	31	1	0	8	0	1	0	1
○	230034	NAGOYA CITY UNIV.	25	0	13	1	0	4	0	0	3	4
○	230035	FUJITA HEALTH UNIV.	17	0	11	1	0	5	0	0	0	0
○	230040	AICHI MED. UNIV.	17	0	9	1	0	5	0	0	0	2
○	230052	AICHI CANCER CENTER	92	0	58	2	0	20	0	0	0	12
○	240002	MIE PREF. GENERAL MED. CENTER	29	0	20	0	0	3	1	0	0	5
○	240003	YOKKAICHI MUNI. HOSP.	6	0	4	0	0	1	0	0	0	1
	240008	MIE CHUO MED. CENTER	4	0	3	0	0	0	0	0	0	1
○	240015	ISE RED CROSS HOSP.	19	0	10	3	0	5	0	0	0	1
	250001	OHTSU RED CROSS HOSP.	18	0	11	0	0	3	0	0	0	4
	250003	SHIGA UNIV. OF MED. SCIENCE	12	3	6	0	0	3	0	0	0	0
○	250006	OMIHACHIMAN COMMUNITY MED. CENTER	5	0	3	0	0	2	0	0	0	0
○	250008	SHIGA MED. CENTER FOR ADULTS	10	0	3	2	0	4	0	0	0	1
	260002	KYOTO 2ND RED CROSS HOSP.	14	0	10	0	0	1	0	0	0	3
○	260003	KYOTO PREF. UNIV. OF MED.	12	0	9	1	0	0	0	0	0	2
○	260007	KYOTO 1ST RED CROSS HOSP.	25	0	13	0	0	6	2	0	0	4
○	260009	KYOTO UNIV.	35	0	19	1	0	11	0	0	0	4
○	260013	KYOTO KATSURA HOSP.	4	0	4	0	0	0	0	0	0	0
○	260014	KYOTO MED. CENTER	24	0	16	0	0	7	0	1	0	0
	260017	SAISEIKAI KYOTO HOSP.	2	0	0	0	0	1	0	0	0	1
○	270003	KITANO HOSP.	34	0	26	1	0	2	0	0	0	5
	270007	OSAKA CITY GENERAL HOSP.	43	43	0	0	0	0	0	0	0	0
○	270009	OSAKA NATIONAL HOSP.	36	0	22	0	0	6	0	0	1	7
	270013	OSAKA POLICE HOSP.	6	0	1	0	0	3	0	0	0	2
	270014	OSAKA RED CROSS HOSP.	16	16	0	0	0	0	0	0	0	0
○	270016	OSAKA CITY UNIV.	45	0	33	1	0	11	0	0	0	0
	270018	NISSAY HOSP.	11	11	0	0	0	0	0	0	0	0
○	270032	SAISEIKAI SUITA HOSP.	9	0	6	1	0	1	0	1	0	0
○	270035	OSAKA UNIV.	65	0	38	9	0	5	0	6	1	12
	270041	OSAKA MED. COLL.	55	0	33	0	0	5	1	0	0	16
○	270042	KANSAI MED. UNIV.	16	1	12	0	0	3	0	0	0	0
	270056	KINKI UNIV.	41	0	0	0	0	0	0	0	0	41
	270060	SAKAI CITY HOSP.	4	0	3	0	0	0	0	0	0	1
○	270062	OSAKA ROUSAI HOSP.	56	0	32	1	0	12	0	1	0	10
○	270101	OSAKA MED. CENTER FOR CANCER AND CARDIOVASCULAR DISEASES	63	0	46	1	0	9	0	1	0	6
○	280001	KOBE UNIV.	32	0	13	9	0	9	1	0	0	0
○	280002	KOBE CITY MED. CENTER GENERAL HOSP.	24	0	13	0	0	8	0	0	0	3
	280010	KOBE MED. CENTER	3	0	2	0	0	0	0	0	0	1
	280012	HYOGO PREF. AWAJI MED. CENTER	10	8	0	0	0	0	0	0	0	2
○	280015	KANSAI ROUSAI HOSP.	26	0	18	1	0	2	0	0	0	5
	280021	HYOGO MED. COLL.	37	37	0	0	0	0	0	0	0	0
	280028	TOYOOKA PUBLIC HOSP.	7	0	4	0	0	1	0	0	0	2
○	280030	HIMEJI RED CROSS HOSP.	15	0	9	1	0	3	0	1	0	1
○	280033	HYOGO CANCER CENTER	115	0	72	7	0	26	0	2	3	5
○	290003	NARA PREF. NARA HOSP.	17	0	15	1	0	1	0	0	0	0
○	290004	TENRI HOSP.	17	0	16	1	0	0	0	0	0	0
○	290007	NARA MED. UNIV.	25	0	18	1	0	4	0	0	0	2
○	290019	YAMATO TAKADA MUNI. HOSP.	1	0	1	0	0	0	0	0	0	0
○	300002	JAPANESE RED CROSS WAKAYAMA MED. CENTER	15	0	9	1	0	3	1	0	0	1
	300003	WAKAYAMA MED. UNIV.	28	0	19	0	0	3	0	0	0	6
○	310001	TOTTORI PREF. CENTRAL HOSP.	12	0	10	0	0	1	0	0	0	1
○	310007	TOTTORI UNIV.	28	0	20	2	0	6	0	0	0	0
○	320004	SHIMANE PREF. CENTRAL HOSP.	11	2	5	1	0	3	0	0	0	0
	330002	JAPANESE RED CROSS OKAYAMA HOSP.	5	0	1	0	0	0	0	0	0	4
	330004	OKAYAMA SAISEIKAI GENERAL HOSP.	27	0	17	0	0	1	0	0	0	9
	330006	OKAYAMA UNIV.	45	0	30	2	0	3	0	0	0	10
○	330007	OKAYAMA MED. CENTER	1	0	1	0	0	0	0	0	0	0

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
	330008 KURASHIKI CENTRAL HOSP.	15	0	7	2	0	1	0	0	0	5
	330009 KAWASAKI MED. SCH.	20	0	8	0	0	3	0	0	1	8
○	330010 KURASHIKI MED. CENTER	41	0	38	1	0	2	0	0	0	0
○	340001 FUKUYAMA MED. CENTER	38	0	22	0	0	11	2	2	0	1
	340007 HIROSHIMA CITY HOSP.	33	0	22	0	0	2	0	1	0	8
	340008 HIROSHIMA RED CROSS HOSP. AND ATOMIC-BOMB SURVIVORS HOSP.	4	0	1	0	0	0	0	0	0	3
○	340010 HIROSHIMA CITY ASA HOSP.	15	0	11	0	0	2	0	1	0	1
○	340012 HIROSHIMA UNIV.	31	0	21	1	0	5	0	1	0	3
○	340014 HIROSHIMA PREF. HOSP.	16	0	8	0	0	5	0	1	0	2
○	340015 KURE MED. CENTER	25	0	13	0	0	6	0	1	0	5
○	340018 HIROSHIMA GENERAL HOSP.	3	0	2	1	0	0	0	0	0	0
	350003 TOKUYAMA CENTRAL HOSP.	17	17	0	0	0	0	0	0	0	0
	350008 YAMAGUCHI RED CROSS HOSP.	12	0	6	2	0	0	1	0	0	3
	350009 YAMAGUCHI UNIV.	19	0	7	0	0	7	0	1	0	4
○	360003 TOKUSHIMA UNIV.	31	0	23	0	0	8	0	0	0	0
	360005 TOKUSHIMA PREF. CENTRAL HOSP.	5	0	3	0	0	0	0	0	0	2
○	370001 TAKAMATSU RED CROSS HOSP.	10	0	3	0	0	5	0	0	0	2
○	380001 SHIKOKU CANCER CENTER	71	0	44	3	0	15	1	0	1	7
	380002 EHIME PREF. CENTRAL HOSP.	4	4	0	0	0	0	0	0	0	0
○	380006 EHIME UNIV.	24	0	12	1	0	3	0	5	0	3
	390003 KOCHI HEALTH SCIENCE CENTER	18	0	11	0	0	3	0	0	0	4
	390006 KOCHI UNIV.	13	0	9	1	0	0	0	0	0	3
○	400008 UNIV. OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH	13	0	8	0	0	4	0	0	0	1
○	400010 KYUSHU MED. CENTER	10	0	7	0	0	2	0	0	0	1
○	400012 KYUSHU UNIV.	66	0	54	2	0	9	0	0	0	1
○	400013 FUKUOKA UNIV.	21	0	14	1	0	6	0	0	0	0
	400014 FUKUOKA RED CROSS HOSP.	6	0	1	0	0	0	1	0	0	4
	400017 IIZUKA HOSP.	31	0	18	1	0	5	0	0	0	7
○	400020 KURUME UNIV.	49	0	33	1	0	14	0	0	0	1
	400026 SAISEIKAI FUKUOKA GENERAL HOSP.	20	0	13	0	0	2	0	0	0	5
○	400040 KYUSHU CANCER CENTER	90	0	68	0	0	13	2	1	2	4
○	410005 SAGA UNIV.	30	0	19	0	0	6	1	0	0	4
○	420001 NAGASAKI HARBOR MED. CENTER CITY HOSP.	13	0	9	0	0	4	0	0	0	0
○	420002 NAGASAKI UNIV.	34	0	23	0	0	8	0	2	0	1
	420003 RED CROSS NAGASAKI ATOMIC BOMB HOSP.	13	0	9	0	0	1	0	0	0	3
	420006 SASEBO KYOSAI HOSP.	22	0	16	0	0	1	0	0	0	5
	430001 KUMAMOTO MED. CENTER	35	0	11	0	0	15	0	0	0	9
○	430002 KUMAMOTO UNIV.	78	0	53	0	0	14	0	1	0	10
	430003 KUMAMOTO CITY HOSP.	4	0	2	0	0	0	0	0	0	2
○	440002 OITA PREF. HOSP.	40	0	23	0	0	9	0	0	0	8
	440003 BEPPU MED. CENTER	13	13	0	0	0	0	0	0	0	0
	440005 OITA UNIV.	12	0	3	0	0	1	0	0	0	8
	450001 MIYAZAKI PREF. HOSP.	54	0	14	1	0	17	1	1	3	17
○	450005 MIYAZAKI UNIV.	37	0	26	0	0	8	1	0	1	1
	460001 KAGOSHIMA UNIV.	30	30	0	0	0	0	0	0	0	0
	460004 KAGOSHIMA CITY HOSP.	39	0	17	1	0	4	0	0	0	17
○	470008 RYUKYU UNIV.	68	0	47	1	0	18	0	0	0	2
	470010 OKINAWA PREF. CHUBU HOSP.	9	0	4	0	0	3	0	0	0	2
	Total	5,390	420	3,088	125	0	947	24	57	26	703

Table 1. No. of Patients by Stage and Age

Age		~19		20~29		30~39		40~49		50~59		60~69		70~79		80~		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I	A1	0	0.0	34	0.9	172	4.7	122	3.3	43	1.2	51	1.4	9	0.2	1	0.0	432	11.8
	A2	0	0.0	2	0.1	17	0.5	15	0.4	8	0.2	3	0.1	2	0.1	0	0.0	47	1.3
	A not cl.	0	0.0	3	0.1	15	0.4	16	0.4	9	0.2	9	0.2	6	0.2	5	0.1	63	1.7
	B1	0	0.0	56	1.5	300	8.2	298	8.1	227	6.2	142	3.9	73	2.0	12	0.3	1,108	30.3
	B2	0	0.0	14	0.4	80	2.2	118	3.2	52	1.4	21	0.6	20	0.5	5	0.1	310	8.5
	B not cl.	0	0.0	2	0.1	7	0.2	7	0.2	5	0.1	3	0.1	5	0.1	4	0.1	33	0.9
	not cl.	0	0.0	0	0.0	0	0.0	2	0.1	1	0.0	1	0.0	0	0.0	2	0.1	6	0.2
total	0	0.0	111	3.0	591	16.2	578	15.8	345	9.4	230	6.3	115	3.1	29	0.8	1,999	54.6	
II	A	0	0.0	3	0.1	32	0.9	45	1.2	47	1.3	49	1.3	30	0.8	21	0.6	227	6.2
	B	0	0.0	11	0.3	74	2.0	138	3.8	157	4.3	134	3.7	89	2.4	41	1.1	644	17.6
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
total	0	0.0	14	0.4	106	2.9	183	5.0	204	5.6	183	5.0	119	3.3	62	1.7	871	23.8	
III	A	0	0.0	0	0.0	1	0.0	6	0.2	15	0.4	11	0.3	15	0.4	8	0.2	56	1.5
	B	0	0.0	6	0.2	34	0.9	59	1.6	98	2.7	100	2.7	92	2.5	46	1.3	435	11.9
	not cl.	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
total	0	0.0	6	0.2	36	1.0	65	1.8	113	3.1	111	3.0	107	2.9	54	1.5	492	13.4	
IV	A	0	0.0	1	0.0	4	0.1	15	0.4	19	0.5	15	0.4	14	0.4	11	0.3	79	2.2
	B	0	0.0	0	0.0	15	0.4	38	1.0	68	1.9	42	1.1	33	0.9	17	0.5	213	5.8
	not cl.	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	2	0.1	0	0.0	0	0.0	4	0.1
total	0	0.0	1	0.0	19	0.5	54	1.5	88	2.4	59	1.6	47	1.3	28	0.8	296	8.1	
Total		0	0.0	132	3.6	752	20.6	880	24.1	750	20.5	583	15.9	388	10.6	173	4.7	3,658	

Table 2. No. of Patients by Treatment method

Treatment		Surgery								Radiation				Chem.Immun. Hormon		Other		Total			
		(alone)		Radiation		Radiation Chem.Immun. Hormon		Chem.Immun. Hormon		(alone)		Chem.Immun. Hormon									
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
I	A1	420	11.5	5	0.1	1	0.0	3	0.1	0	0.0	0	0.0	0	0.0	0	0.0	3	0.1	432	11.8
	A2	45	1.2	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	47	1.3
	A not cl.	56	1.5	0	0.0	0	0.0	1	0.0	6	0.2	0	0.0	0	0.0	0	0.0	0	0.0	63	1.7
	B1	628	17.2	95	2.6	83	2.3	177	4.8	83	2.3	29	0.8	2	0.1	11	0.3	1,108	30.3		
	B2	53	1.4	34	0.9	71	1.9	105	2.9	21	0.6	22	0.6	0	0.0	4	0.1	310	8.5		
	B not cl.	11	0.3	5	0.1	10	0.3	3	0.1	4	0.1	0	0.0	0	0.0	0	0.0	33	0.9		
	not cl.	0	0.0	2	0.1	0	0.0	1	0.0	2	0.1	0	0.0	0	0.0	1	0.0	6	0.2		
total	1,213	33.2	143	3.9	165	4.5	290	7.9	116	3.2	51	1.4	2	0.1	19	0.5	1,999	54.6			
II	A	42	1.1	26	0.7	33	0.9	43	1.2	49	1.3	29	0.8	1	0.0	4	0.1	227	6.2		
	B	35	1.0	51	1.4	110	3.0	109	3.0	103	2.8	208	5.7	3	0.1	25	0.7	644	17.6		
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
total	77	2.1	77	2.1	143	3.9	152	4.2	152	4.2	237	6.5	4	0.1	29	0.8	871	23.8			
III	A	0	0.0	0	0.0	2	0.1	0	0.0	18	0.5	31	0.8	1	0.0	4	0.1	56	1.5		
	B	0	0.0	0	0.0	3	0.1	11	0.3	135	3.7	258	7.1	5	0.1	23	0.6	435	11.9		
	not cl.	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0		
total	0	0.0	0	0.0	6	0.2	11	0.3	153	4.2	289	7.9	6	0.2	27	0.7	492	13.4			
IV	A	0	0.0	0	0.0	0	0.0	0	0.0	31	0.8	37	1.0	3	0.1	8	0.2	79	2.2		
	B	1	0.0	1	0.0	3	0.1	11	0.3	44	1.2	101	2.8	47	1.3	5	0.1	213	5.8		
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.1	0	0.0	1	0.0	4	0.1		
total	1	0.0	1	0.0	3	0.1	11	0.3	75	2.1	141	3.9	50	1.4	14	0.4	296	8.1			
Total		1,291	35.3	221	6.0	317	8.7	464	12.7	496	13.6	718	19.6	62	1.7	89	2.4	3,658			

Table 3. No. of Patients by Histological Type

Histological Type		Squamous Cell Cancer						Adenocarcinoma												Adenosquamous carcinoma			
		unknown		keratinizing		non-keratinizing		unknown		mucinous-endocervical		mucinous-intestinal		endometrioid		clear cell		serous				mesonephric	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%			No.	%
I	A1	230	6.3	23	0.6	148	4.0	7	0.2	11	0.3	1	0.0	1	0.0	2	0.1	0	0.0	0	0.0	6	0.2
	A2	26	0.7	5	0.1	11	0.3	1	0.0	2	0.1	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	A not cl.	14	0.4	0	0.0	5	0.1	24	0.7	14	0.4	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	4	0.1
	B1	166	4.5	140	3.8	381	10.4	51	1.4	189	5.2	11	0.3	47	1.3	11	0.3	5	0.1	0	0.0	69	1.9
	B2	43	1.2	39	1.1	110	3.0	13	0.4	38	1.0	5	0.1	11	0.3	2	0.1	1	0.0	0	0.0	24	0.7
	B not cl.	5	0.1	5	0.1	15	0.4	3	0.1	3	0.1	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0
	not cl.	1	0.0	2	0.1	1	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
total	485	13.3	214	5.9	671	18.3	99	2.7	258	7.1	17	0.5	62	1.7	15	0.4	6	0.2	0	0.0	105	2.9	
II	A	55	1.5	31	0.8	95	2.6	8	0.2	14	0.4	1	0.0	3	0.1	2	0.1	1	0.0	0	0.0	12	0.3
	B	116	3.2	105	2.9	291	8.0	22	0.6	60	1.6	1	0.0	14	0.4	4	0.1	0	0.0	0	0.0	16	0.4
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	total	171	4.7	136	3.7	386	10.6	30	0.8	74	2.0	2	0.1	17	0.5	6	0.2	1	0.0	0	0.0	28	0.8
III	A	19	0.5	7	0.2	20	0.5	3	0.1	2	0.1	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0
	B	141	3.9	71	1.9	162	4.4	17	0.5	19	0.5	2	0.1	2	0.1	0	0.0	1	0.0	0	0.0	10	0.3
	not cl.	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	total	160	4.4	78	2.1	183	5.0	20	0.5	21	0.6	2	0.1	2	0.1	1	0.0	1	0.0	0	0.0	10	0.3
IV	A	28	0.8	10	0.3	32	0.9	3	0.1	2	0.1	1	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0
	B	54	1.5	23	0.6	69	1.9	16	0.4	11	0.3	0	0.0	6	0.2	0	0.0	3	0.1	0	0.0	12	0.3
	not cl.	2	0.1	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	total	84	2.3	33	0.9	103	2.8	19	0.5	13	0.4	1	0.0	8	0.2	0	0.0	3	0.1	0	0.0	12	0.3
Total	900	24.6	461	12.6	1,343	36.7	168	4.6	366	10.0	22	0.6	89	2.4	22	0.6	11	0.3	0	0.0	155	4.2	

Histological Type		Others																Total					
		glassy cell		adenoid cystic		adeno basal		carcinoid		small cell		undifferentiated		carcinosarcoma		other				unknown			
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%			No.	%		
I	A1	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	432	11.8
	A2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	47	1.3		
	A not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	63	1.7		
	B1	7	0.2	0	0.0	0	0.0	1	0.0	14	0.4	5	0.1	0	0.0	10	0.3	1	0.0	1,108	30.3		
	B2	4	0.1	1	0.0	0	0.0	0	0.0	8	0.2	3	0.1	2	0.1	6	0.2	0	0.0	310	8.5		
	B not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	33	0.9		
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	0.2		
total	12	0.3	2	0.1	0	0.0	1	0.0	22	0.6	8	0.2	4	0.1	17	0.5	1	0.0	1,999	54.6			
II	A	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	1	0.0	2	0.1	0	0.0	0	0.0	227	6.2
	B	2	0.1	0	0.0	0	0.0	0	0.0	6	0.2	5	0.1	0	0.0	2	0.1	0	0.0	644	17.6		
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
total	2	0.1	0	0.0	0	0.0	0	0.0	8	0.2	5	0.1	1	0.0	4	0.1	0	0.0	871	23.8			
III	A	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	56	1.5
	B	0	0.0	1	0.0	1	0.0	0	0.0	2	0.1	4	0.1	0	0.0	2	0.1	0	0.0	435	11.9		
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0		
total	0	0.0	1	0.0	1	0.0	0	0.0	4	0.1	5	0.1	1	0.0	2	0.1	0	0.0	492	13.4			
IV	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	79	2.2
	B	1	0.0	0	0.0	0	0.0	0	0.0	10	0.3	1	0.0	0	0.0	5	0.1	2	0.1	213	5.8		
	not cl.	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	0.1		
total	1	0.0	0	0.0	0	0.0	0	0.0	10	0.3	2	0.1	0	0.0	5	0.1	2	0.1	296	8.1			
Total	15	0.4	3	0.1	1	0.0	1	0.0	44	1.2	20	0.5	6	0.2	28	0.8	3	0.1	3,658				

Table 4. 5-Year Results, Treatment Started in 2008

5-year result	No. of patients	%
Alive with no evidence of the disease	2,454	67.1
Alive with carcinoma	100	2.7
Alive with or without carcinoma unknown	0	0.0
Died of carcinoma	736	20.1
Died of other malignant tumor	20	0.5
Died of intercurrent disease	43	1.2
Cause of death unknown	21	0.6
Lost to follow-up	284	7.8
Total	3,658	

Table 5. 5-Year Survival by Stage, Treatment Started in 2008

FIGO Stage		Patients treated		5-year survival		Lost to follow-up
		No.		%		
I	A1	432	1,999	99.5	93.0	164/1999(8.2%)
	A2	47		100.0		
	A not cl.	63		95.0		
	B1	1,108		94.1		
	B2	310		81.1		
	B not cl. not cl.	33 6		80.7 80.0		
II	A	227	871	77.6	73.1	67/871(7.7%)
	B	644		71.5		
	not cl.	0				
III	A	56	492	66.1	55.2	34/492(6.9%)
	B	435		54.0		
	not cl.	1		0.0		
IV	A	79	296	41.2	24.2	19/296(6.4%)
	B	213		17.3		
	not cl.	4		50.0		
Total		3,658				

Table 6. 5-Year Survival by Histological Type, Treatment Started in 2008

Histological Type	Patients treated		5-year survival	Lost to follow-up
	No.	%	%	
Squamous cell carcinoma	2,704	73.9	80.0	230/2704(8.5%)
Adenocarcinoma	678	18.5	73.7	36/678(5.3%)
Adenosquamous carcinoma	155	4.2	80.0	11/155(7.1%)
Others	121	3.3	52.9	7/121(5.8%)
Total	3,658			


Table 7. 5-Year Survival by Stage and Histological Type, Treatment Started in 2008

FIGO Stage	Histology Type	Patients treated		5-year survival	Lost to follow-up
		No.	%	%	
I	Squamous cell carcinoma	1,370	68.5	94.9	132/1999(6.6%)
	Adenocarcinoma	457	22.9	91.1	21/1999(1.1%)
	Adenosquamous carcinoma	105	5.3	93.1	7/1999(0.4%)
	Others	67	3.4	69.2	4/1999(0.2%)
II	Squamous cell carcinoma	693	79.6	78.2	53/871(6.1%)
	Adenocarcinoma	130	14.9	51.3	9/871(1.0%)
	Adenosquamous carcinoma	28	3.2	62.4	3/871(0.3%)
	Others	20	2.3	59.6	2/871(0.2%)
III	Squamous cell carcinoma	421	85.6	60.1	29/492(5.9%)
	Adenocarcinoma	47	9.6	17.2	4/492(0.8%)
	Adenosquamous carcinoma	10	2.0	50.0	0/492(0.0%)
	Others	14	2.8	33.0	1/492(0.2%)
IV	Squamous cell carcinoma	220	74.3	28.7	16/296(5.4%)
	Adenocarcinoma	44	14.9	10.3	2/296(0.7%)
	Adenosquamous carcinoma	12	4.1	31.3	1/296(0.3%)
	Others	20	6.8	0.0	0/296(0.0%)

Table 8. 5-Year Survival by TNM Classification, Treatment Started in 2008

TNM Stage			Patients treated		5-year survival	Lost to follow-up
			No.	%	%	
T1a1	N0	M0	363	10.4	99.1	59/363(16.3%)
T1a2	N0	M0	45	1.3	97.6	8/45(17.8%)
T1b1	N0	M0	1,030	29.6	94.9	56/1030(5.4%)
T1b2	N0	M0	242	7.0	82.8	12/242(5.0%)
T2a	N0	M0	191	5.5	79.9	13/191(6.8%)
T2b	N0	M0	401	11.5	76.3	31/401(7.7%)
T3a	N0	M0	35	1.0	70.3	3/35(8.6%)
T3b	N0	M0	207	5.9	62.6	19/207(9.2%)
T4	N0	M0	42	1.2	48.6	3/42(7.1%)
T1a1	N1	M0	0	0.0	—	—
T1a2	N1	M0	1	0.0	100.0	0/1(0.0%)
T1b1	N1	M0	65	1.9	82.6	1/65(1.5%)
T1b2	N1	M0	68	2.0	75.5	2/68(2.9%)
T2a	N1	M0	33	0.9	62.5	1/33(3.0%)
T2b	N1	M0	211	6.1	64.4	17/211(8.1%)
T3a	N1	M0	17	0.5	62.5	0/17(0.0%)
T3b	N1	M0	176	5.1	48.8	11/176(6.3%)
T4	N1	M0	21	0.6	44.0	0/21(0.0%)
Any T	Any N	MA	148	4.3	40.8	8/148(5.4%)
Any T	Any N	M1	183	5.3	15.0	14/183(7.7%)
Any T	Any N	MA/M1	331	9.5	26.9	22/331(6.6%)


Figure 1.
Kaplan-Meier Estimated Overall Survival Curves of Cervical Cancer Patients by FIGO Stage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr >Chi-Square
Log-rank	1340.9169	3	<.0001
Wilcoxon	1371.2191	3	<.0001
-2Log(LR)	947.6676	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	255.9000	<.0001	<.0001
I	III	580.9000	<.0001	<.0001
I	IV	1017.9000	<.0001	<.0001
II	III	26.8196	<.0001	<.0001
II	IV	96.1732	<.0001	<.0001
III	IV	23.3407	<.0001	<.0001


Figure 2.
Kaplan-Meier Estimated Overall Survival Curves of Cervical Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	72.9290	3	<.0001
Wilcoxon	78.1569	3	<.0001
-2Log(LR)	55.9220	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Squamous cell carcinoma	Adenocarcinoma	17.6006	<.0001	0.0002
Squamous cell carcinoma	Adenosquamous carcinoma	14.8081	0.0001	0.0007
Squamous cell carcinoma	Others	46.7506	<.0001	<.0001
Adenocarcinoma	Adenosquamous carcinoma	6.9295	0.0085	0.0422
Adenocarcinoma	Others	0.0953	0.7576	0.9898
Adenosquamous carcinoma	Others	26.1333	<.0001	<.0001


Figure 3.
Kaplan-Meier Estimated Overall Survival Curves of Cervical Cancer Patients by FIGO Stage I Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	93.0689	3	<.0001
Wilcoxon	98.7494	3	<.0001
-2Log(LR)	91.3029	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	Pr>Chi-Square	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
1A1	1A2	19.6332	<.0001	<.0001
1A1	1B1	4.5403	0.0331	0.1433
1A1	1B2	80.9692	<.0001	<.0001
1A2	1B1	0.2391	0.6248	0.9616
1A2	1B2	73.0203	<.0001	<.0001
1B1	1B2	24.7869	<.0001	<.0001


Figure 4.
Kaplan-Meier Estimated Overall Survival Curves of Stage I Cervical Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	88.6762	3	<.0001
Wilcoxon	89.3285	3	<.0001
-2Log(LR)	52.1300	3	<.0001


Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Squamous cell carcinoma	Adenocarcinoma	21.4728	<.0001	<.0001
Squamous cell carcinoma	Adenosquamous carcinoma	23.8237	<.0001	<.0001
Squamous cell carcinoma	Others	61.5930	<.0001	<.0001
Adenocarcinoma	Adenosquamous carcinoma	4.3361	0.0373	0.1588
Adenocarcinoma	Others	0.4192	0.5173	0.9165
Adenosquamous carcinoma	Others	21.8159	<.0001	<.0001

Figure 5.
Kaplan-Meier Estimated Overall Survival Curves of Cervical Cancer Patients by
FIGO Stage II Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	2.6725	1	0.1021
Wilcoxon	2.8336	1	0.0923
-2Log(LR)	2.8928	1	0.0890


Figure 6.
Kaplan-Meier Estimated Overall Survival Curves of Stage II Cervical Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	52.5701	3	<.0001
Wilcoxon	56.1486	3	<.0001
-2Log(LR)	44.3712	3	<.0001


Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Squamous cell carcinoma	Adenocarcinoma	50.1921	<.0001	<.0001
Squamous cell carcinoma	Adenosquamous carcinoma	39.8067	<.0001	<.0001
Squamous cell carcinoma	Others	48.2035	<.0001	<.0001
Adenocarcinoma	Adenosquamous carcinoma	24.8029	<.0001	<.0001
Adenocarcinoma	Others	24.6213	<.0001	<.0001
Adenosquamous carcinoma	Others	0.1757	0.6751	0.9752

Figure 7.
Kaplan-Meier Estimated Overall Survival Curves of Cervical Cancer Patients by FIGO Stage III Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	2.8702	1	0.0902
Wilcoxon	2.9624	1	0.0852
-2Log(LR)	3.6447	1	0.0562


Figure 8.
Kaplan-Meier Estimated Overall Survival Curves of Stage III Cervical Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	35.2931	3	<.0001
Wilcoxon	30.6063	3	<.0001
-2Log(LR)	32.8730	3	<.0001


Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Squamous cell carcinoma	Adenocarcinoma	33.6849	<.0001	<.0001
Squamous cell carcinoma	Adenosquamous carcinoma	20.1933	<.0001	<.0001
Squamous cell carcinoma	Others	27.3204	<.0001	<.0001
Adenocarcinoma	Adenosquamous carcinoma	20.3336	<.0001	<.0001
Adenocarcinoma	Others	15.4525	<.0001	0.0005
Adenosquamous carcinoma	Others	1.1095	0.2922	0.7179

Figure 9.
Kaplan-Meier Estimated Overall Survival Curves of Cervical Cancer Patients by
FIGO Stage IV Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	16.3686	1	<.0001
Wilcoxon	15.8354	1	<.0001
-2Log(LR)	24.1191	1	<.0001

Figure 10.
Kaplan-Meier Estimated Overall Survival Curves of Stage IV Cervical Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	27.9153	3	<.0001
Wilcoxon	24.0720	3	<.0001
-2Log(LR)	33.4919	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Squamous cell carcinoma	Adenocarcinoma	14.9712	0.0001	0.0006
Squamous cell carcinoma	Adenosquamous carcinoma	5.5378	0.0186	0.0863
Squamous cell carcinoma	Others	19.8382	<.0001	<.0001
Adenocarcinoma	Adenosquamous carcinoma	9.6752	0.0019	0.0101
Adenocarcinoma	Others	0.6024	0.4377	0.8653
Adenosquamous carcinoma	Others	9.9315	0.0016	0.0088

子宮体癌治療成績

Statement for the Year 2008, Inclusive, Corpus

Table A. 5-Year Results, Stage I-IV

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
○	010003	HOKKAIDO CANCER CENTER	21	0	16	2	0	2	0	0	1
○	010024	NTT EAST JAPAN SAPPORO HOSP.	9	0	7	0	0	1	0	0	1
○	010025	SAPPORO MED. UNIV.	40	0	33	1	0	2	0	0	4
○	010027	HOKKAIDO UNIV.	27	0	25	1	0	0	0	0	1
○	010028	KKR SAPPORO MED. CENTER	9	0	7	0	0	2	0	0	0
○	010037	ASAHIKAWA-KOSEI GENERAL HOSP.	11	11	0	0	0	0	0	0	0
○	010038	ASAHIKAWA MED. UNIV.	24	0	15	0	0	1	1	0	7
○	010040	ASAHIKAWA MED. COLL.	30	0	25	0	0	4	1	0	0
○	020004	AOMORI PREF. CENTRAL HOSP.	9	9	0	0	0	0	0	0	0
○	020008	MUTSU GENERAL HOSP.	8	0	4	0	0	2	0	0	2
○	020012	HIROSAKI UNIV.	19	0	13	0	0	3	1	0	2
○	020017	MISAWA CITY HOSP.	3	0	3	0	0	0	0	0	0
○	030004	IWATE MED. UNIV.	1	1	0	0	0	0	0	0	0
○	040004	TOHOKU UNIV.	65	0	47	0	0	8	0	0	10
○	040008	MIYAGI CANCER CENTER	31	0	22	2	0	2	0	0	5
○	040013	SENDAI MED. CENTER	28	20	0	0	0	2	0	1	5
○	050001	AKITA RED CROSS HOSP.	5	0	5	0	0	0	0	0	0
○	050003	AKITA UNIV.	31	0	20	0	0	5	0	0	6
○	060002	YAMAGATA PREF. CENTRAL HOSP.	13	0	10	0	0	2	0	1	0
○	060005	YAMAGATA UNIV.	35	0	27	2	0	2	2	1	1
○	080001	TSUCHIURA KYODO GENERAL HOSP	12	0	9	0	0	2	0	1	0
○	080006	TSUKUBA GAKUEN HOSP.	3	0	2	0	0	0	0	0	1
○	080007	TSUKUBA UNIV.	75	2	63	2	0	5	1	0	2
○	080021	HITACHI GENERAL HOSP.	16	16	0	0	0	0	0	0	0
○	080031	TSUKUBA MED. CENTER	11	0	9	0	0	2	0	0	0
○	090001	TOCHIGI MED. CENTER	2	0	1	0	0	1	0	0	0
○	090004	DOKKYO MED. UNIV.	32	0	24	0	0	3	0	0	5
○	090005	SAISEIKAI UTSUNOMIYA HOSP.	20	0	13	0	0	3	0	0	4
○	090011	ASHIKAGA RED CROSS HOSP.	19	0	9	0	0	3	0	1	6
○	090015	JICHI MED. UNIV.	42	0	31	2	0	6	0	0	3
○	090016	TOCHIGI CANCER CENTER	28	0	23	0	0	4	0	0	1
○	100012	GUNMA UNIV.	40	0	31	0	0	3	1	0	5
○	110008	SAITAMA MED. CENTER	15	0	12	0	0	3	0	0	0
○	110014	KOSHIGAYA MUNI. HOSP.	23	0	22	0	0	1	0	0	0
○	110023	SAITAMA NATIONAL HOSP.	21	0	20	0	0	1	0	0	0
○	110027	NATIONAL DEFENSE MED. COLL.	33	33	0	0	0	0	0	0	0
○	110030	SAITAMA CANCER CENTER	67	0	55	1	0	9	1	0	0
○	110055	SAITAMA INTERNATIONAL MED. CENTER	51	0	30	1	0	6	0	0	14
○	120005	CHIBA UNIV.	42	0	24	1	0	9	0	0	8
○	120009	NIPPON MED. SCH. CHIBA HOKUSOU HOSP.	16	16	0	0	0	0	0	0	0
○	120012	MATSUDO CITY HOSP.	7	0	6	0	0	1	0	0	0
○	120015	TOKYO DENTAL COLL. ICHIKAWA GENERAL HOSP.	23	0	13	0	0	4	1	1	3
○	120021	JIKEI UNIV. KASHIWA HOSP.	54	31	16	0	0	4	0	0	3
○	120023	JUNTENDO UNIV. URAYASU HOSP.	20	0	13	1	0	3	0	0	3
○	120025	TOHO UNIV. SAKURA MED. CENTER	17	0	11	0	0	1	0	0	5
○	120029	ASAHI CENTRAL HOSP.	23	23	0	0	0	0	0	0	0
○	120035	KAMEDA MED. CENTER	34	0	22	0	0	5	0	0	7
○	120042	CHIBA CANCER CENTER	35	0	27	1	0	4	3	0	0
○	120043	NATIONAL INS. OF RADIOLOGICAL SCIENCES	2	0	1	0	0	1	0	0	0
○	130005	mitsui MEMORIAL HOSP.	20	0	14	1	0	3	0	1	1
○	130009	NATIONAL CANCER CENTER	68	0	47	1	0	7	0	0	12
○	130013	JIKEI UNIV.	29	0	20	0	0	4	0	1	4
○	130023	JUNTENDO UNIV.	37	0	22	0	0	10	0	1	4
○	130024	TOKYO MED. DENT. UNIV.	22	0	17	0	0	1	0	0	4

	A	B	C	D	E	F	G	H	I	J	K	
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up	
○	130025	NIPPON MED. SCH.	20	0	13	0	0	2	0	1	0	4
○	130026	TOKYO UNIV.	41	0	27	5	0	5	0	1	0	3
○	130029	TOKYO WOMENS MED. UNIV. MED. CENTER EAST	13	0	9	1	0	1	0	0	0	2
	130034	HIKEI UNIV. KATSUSHIKA MED. CENTER	23	23	0	0	0	0	0	0	0	0
	130038	TOKYO METRO. BOKUTOH HOSP.	9	9	0	0	0	0	0	0	0	0
	130044	NTT MED. CENTER TOKYO	14	0	9	1	0	1	0	0	0	3
	130046	SHOWA UNIV.	30	0	20	0	0	1	0	0	0	9
	130050	TOHO UNIV. OMORI MED. CENTER	24	0	14	0	0	3	1	1	0	5
○	130055	RED CROSS MED. CENTER	15	0	10	0	0	4	0	1	0	0
○	130061	TOKYO MED. CENTER	25	0	18	0	0	5	0	0	0	2
○	130063	KOSEI CENTRAL HOSP.	1	0	1	0	0	0	0	0	0	0
○	130064	TOHO UNIV. OHASHI MED. CENTER	12	0	9	1	0	2	0	0	0	0
	130074	TOKYO MED. UNIV.	38	0	19	1	0	2	0	0	0	16
○	130077	KEIO UNIV.	83	0	66	1	0	12	2	0	0	2
	130080	NATIONAL CENTER FOR GLOBAL HEALTH AND MED.	12	12	0	0	0	0	0	0	0	0
	130081	TOKYO WOMENS MED. HOSP.	27	0	14	0	0	2	0	0	0	11
○	130085	KOSEI HOSP.	8	0	2	0	0	4	0	1	0	1
○	130092	TEIKYO UNIV.	22	0	14	0	0	4	0	0	0	4
○	130095	NIHON UNIV.	32	0	22	1	0	5	1	0	0	3
○	130099	MUSASHINO RED CROSS HOSP.	41	0	32	1	0	2	0	1	1	4
○	130100	KYORIN UNIV.	36	0	25	0	0	4	0	0	0	7
○	130102	TOKYO METRO. TAMA MED. CENTER	35	0	23	0	0	8	0	0	0	4
	130107	TACHIKAWA HOSP.	21	0	7	1	0	3	0	0	0	10
○	130112	MACHIDA MUNI. HOSP.	9	0	8	0	0	1	0	0	0	0
	130119	NIPPON MED. SCH. TAMA NAGAYAMA HOSP.	7	7	0	0	0	0	0	0	0	0
○	130122	TOKYO METRO. KOMAGOME HOSP.	42	0	31	1	0	4	0	0	1	5
	130124	KYOUNDO HOSP.	7	0	5	0	0	0	0	0	0	2
○	130125	CANCER INST. HOSP.	145	0	127	7	0	9	1	0	0	1
	130135	TAMA-NAMBU SHIKI HOSP.	16	16	0	0	0	0	0	0	0	0
	130137	TOKAI UNIV. HACHIOJI HOSP.	10	10	0	0	0	0	0	0	0	0
	140006	NIPPON MED. SCH. MUSASHI KOSUGI HOSP.	19	0	12	0	0	2	0	0	0	5
○	140008	KANTO ROSAI HOSP.	5	0	4	0	0	0	1	0	0	0
○	140012	ST. MARIANNA UNIV.	37	0	25	1	0	8	0	0	0	3
○	140016	YOKOHAMA ROSAI HOSP.	17	0	15	0	0	1	0	0	0	1
	140017	SHOWA UNIV. FUJIGAOKA HOSP.	22	0	15	1	0	1	0	0	0	5
○	140020	KITASATO UNIV.	76	0	48	3	0	12	0	0	0	13
○	140029	YOKOHAMA CITY UNIV.	36	0	27	1	0	6	1	0	1	0
	140030	YOKOHAMA MINAMI KYOSAI HOSP.	8	0	5	1	0	0	0	0	0	2
	140035	YOKOHAMA MUNI. CITIZENS HOSP.	26	0	11	2	0	5	0	0	0	8
	140037	ST. MARIANNA UNIV. YOKOHAMA CITY SEBU HOSP.	9	0	6	0	0	0	0	0	0	3
○	140044	SHONAN KAMAKURA GENERAL HOSP.	16	0	10	0	0	3	0	0	0	3
○	140054	ISEHARA KYODO HOSP.	7	0	4	0	0	1	1	1	0	0
	140055	TOKAI UNIV.	47	0	23	2	0	6	1	0	0	15
○	140059	KANAGAWA CANCER CENTER	70	0	57	2	0	8	0	2	0	1
	140061	YOKOHAMA CITY UNIV. MED. CENTER	11	0	5	0	0	2	0	0	1	3
○	150002	YAMANASHI PREF. CENTRAL HOSP.	38	0	28	1	0	4	0	0	0	5
○	150006	UNIV. OF YAMANASHI	16	0	10	0	0	4	0	0	0	2
○	160001	NAGANO RED CROSS HOSP.	19	0	15	0	0	1	0	0	0	3
○	160022	NAGANO MUNI. HOSP.	26	0	21	0	0	3	0	0	0	2
	170006	FUJI CITY GENERAL HOSP.	1	1	0	0	0	0	0	0	0	0
○	170009	SHIZUOKA GENERAL HOSP.	26	0	18	0	0	4	0	0	0	4
○	180001	NAGAOKA RED CROSS HOSP.	26	0	23	1	0	1	0	0	0	1
○	180010	NIIGATA CANCER CENTER HOSP.	40	0	30	0	0	3	1	0	0	6
○	190001	TOYAMA UNIV.	10	0	5	1	0	2	0	0	0	2
	190002	TOYAMA RED CROSS HOSP.	7	0	4	0	0	1	0	0	0	2
○	190009	TAKAOKA CITY HOSP.	11	0	9	0	0	2	0	0	0	0
○	200001	KANAZAWA MED. UNIV.	11	0	9	2	0	0	0	0	0	0
○	200002	KANAZAWA MED. CENTER	8	0	7	0	0	1	0	0	0	0
○	200004	KANAZAWA UNIV.	22	0	19	1	0	0	0	0	0	2

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
	210002 FUKUI PREF. HOSP.	13	0	8	0	0	2	0	0	0	3
○	210004 FUKUI RED CROSS UNIV.	11	0	8	0	0	3	0	0	0	0
○	220002 GIFU UNIV.	40	0	24	2	0	6	0	1	5	2
○	220006 OGAKI MUNI. HOSP.	42	0	34	0	0	7	0	0	0	1
○	230001 TOYOHASHI MUNI. HOSP.	27	0	21	0	0	3	0	0	0	3
○	230014 RED CROSS NAGOYA DAICHI HOSP.	19	0	16	0	0	1	0	0	0	2
○	230031 NAGOYA UNIV.	41	0	31	2	0	3	0	0	0	5
○	230034 NAGOYA CITY UNIV.	16	0	14	1	0	0	0	0	0	1
○	230035 FUJITA HEALTH UNIV.	17	0	14	0	0	3	0	0	0	0
○	230040 AICHI MED. UNIV.	17	0	13	0	0	2	0	0	0	2
○	230052 AICHI CANCER CENTER	42	0	35	1	0	6	0	0	0	0
○	240002 MIE PREF. GENERAL MED. CENTER	16	0	11	0	0	2	0	0	0	3
	240003 YOKKAICHI MUNI. HOSP	7	0	3	0	0	1	0	0	0	3
○	240008 MIE CHUO MED. CENTER	23	0	15	0	0	4	0	0	0	4
○	240015 ISE RED CROSS HOSP.	16	0	11	2	0	3	0	0	0	0
	250001 OHTSU RED CROSS HOSP.	11	0	3	2	0	1	0	0	0	5
	250003 SHIGA UNIV. OF MED. SCIENCE	11	11	0	0	0	0	0	0	0	0
	250006 OMIHACHIMAN COMMUNITY MED. CENTER	8	0	4	0	0	2	0	0	0	2
○	250008 SHIGA MED. CENTER FOR ADULTS	16	0	13	0	0	2	0	0	0	1
	260002 KYOTO 2ND RED CROSS HOSP.	20	0	12	0	0	3	0	0	0	5
○	260003 KYOTO PREF. UNIV. OF MED.	7	0	5	0	0	2	0	0	0	0
○	260007 KYOTO 1ST RED CROSS HOSP.	18	0	17	0	0	1	0	0	0	0
○	260009 KYOTO UNIV.	34	0	23	1	0	6	0	0	0	4
○	260013 KYOTO KATSURA HOSP.	4	0	4	0	0	0	0	0	0	0
○	260014 KYOTO MED. CENTER	24	0	17	1	0	2	0	0	0	4
○	260017 SAISEIKAI KYOTO HOSP.	3	0	3	0	0	0	0	0	0	0
○	270003 KITANO HOSP.	29	0	22	1	0	2	0	0	1	3
○	270007 OSAKA CITY GENERAL HOSP.	23	0	20	2	0	1	0	0	0	0
○	270009 OSAKA NATIONAL HOSP.	29	0	18	0	0	8	0	0	2	1
○	270013 OSAKA POLICE HOSP.	10	0	9	0	0	0	0	0	0	1
	270014 OSAKA RED CROSS HOSP.	26	26	0	0	0	0	0	0	0	0
○	270016 OSAKA CITY UNIV.	26	0	19	1	0	6	0	0	0	0
	270018 NISSAY HOSP.	10	10	0	0	0	0	0	0	0	0
○	270032 SAISEIKAI SUITA HOSP.	16	0	9	0	0	2	1	0	1	3
○	270035 OSAKA UNIV.	61	0	45	0	0	5	0	0	1	10
○	270041 OSAKA MED. COLL.	39	0	29	0	0	6	0	0	0	4
○	270042 KANSAI MED. UNIV.	28	0	18	0	0	4	1	0	0	5
	270056 KINKI UNIV.	32	0	0	0	0	0	0	0	0	32
○	270060 SAKAI CITY HOSP.	17	0	14	0	0	0	0	0	0	3
○	270062 OSAKA ROUSAI HOSP.	33	0	26	1	0	4	0	0	0	2
○	270101 OSAKA MED. CENTER FOR CANCER AND CARDIOVASCULAR DISEASES	43	0	32	1	0	8	1	0	0	1
○	280001 KOBE UNIV.	28	0	22	3	0	2	0	1	0	0
○	280002 KOBE CITY MED. CENTER GENERAL HOSP.	22	0	15	3	0	3	0	0	0	1
○	280010 KOBE MED. CENTER	6	0	6	0	0	0	0	0	0	0
	280012 HYOGO PREF. AWAJI MED. CENTER	8	8	0	0	0	0	0	0	0	0
○	280015 KANSAI ROUSAI HOSP.	17	0	14	0	0	3	0	0	0	0
	280021 HYOGO MED. COLL.	28	28	0	0	0	0	0	0	0	0
○	280028 TOYOOKA PUBLIC HOSP.	9	0	7	0	0	1	0	1	0	0
○	280030 HIMEJI RED CROSS HOSP.	22	0	18	1	0	1	0	0	0	2
○	280033 HYOGO CANCER CENTER	100	0	79	3	0	14	0	2	0	2
○	290003 NARA PREF. NARA HOSP.	12	0	9	1	0	0	0	0	0	2
○	290004 TENRI HOSP.	22	0	16	1	0	4	1	0	0	0
○	290007 NARA MED. UNIV.	25	0	17	1	0	4	1	1	0	1
○	290019 YAMATO TAKADA MUNI. HOSP.	7	0	7	0	0	0	0	0	0	0
○	300002 JAPANESE RED CROSS WAKAYAMA MED. CENTER	27	0	17	1	0	3	0	4	0	2
	300003 WAKAYAMA MED. UNIV.	18	0	10	0	0	2	0	0	0	6
○	310001 TOTTORI PREF. CENTRAL HOSP.	8	0	6	0	0	2	0	0	0	0
○	310007 TOTTORI UNIV.	22	0	16	1	0	5	0	0	0	0
○	320004 SHIMANE PREF. CENTRAL HOSP.	13	1	9	0	0	3	0	0	0	0

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
	330002 JAPANESE RED CROSS OKAYAMA HOSP.	8	0	5	0	0	1	0	0	0	2
○	330003 KAWASAKI HOSP.	1	0	1	0	0	0	0	0	0	0
	330004 OKAYAMA SAISEIKAI GENERAL HOSP.	9	0	5	0	0	0	1	0	0	3
○	330006 OKAYAMA UNIV.	34	0	20	0	0	8	0	0	3	3
○	330007 OKAYAMA MED. CENTER	2	0	2	0	0	0	0	0	0	0
○	330008 KURASHIKI CENTRAL HOSP.	25	0	15	0	0	3	3	0	1	3
○	330009 KAWASAKI MED. SCH.	13	0	8	0	0	3	1	0	0	1
○	330010 KURASHIKI MED. CENTER	30	0	24	0	0	5	0	0	0	1
○	340001 FUKUYAMA MED. CENTER	20	0	16	1	0	3	0	0	0	0
	340007 HIROSHIMA CITY HOSP.	50	0	32	0	0	3	0	0	0	15
○	340008 HIROSHIMA RED CROSS HOSP. AND ATOMIC BOMB SURVIVORS HOSP.	4	0	3	0	0	1	0	0	0	0
○	340010 HIROSHIMA CITY ASA HOSP.	14	0	12	0	0	2	0	0	0	0
○	340012 HIROSHIMA UNIV.	34	0	26	1	0	1	0	2	0	4
○	340014 HIROSHIMA PREF. HOSP.	16	0	12	0	0	1	0	0	1	2
○	340015 KURE MED. CENTER	29	0	21	1	0	3	0	1	0	3
	340018 HIROSHIMA GENERAL HOSP.	13	0	9	0	0	1	0	0	0	3
	350003 TOKUYAMA CENTRAL HOSP.	29	29	0	0	0	0	0	0	0	0
	350008 YAMAGUCHI RED CROSS HOSP.	9	0	4	0	0	1	0	0	0	4
○	350009 YAMAGUCHI UNIV.	17	0	8	1	0	4	0	0	1	3
	360002 TOKUSHIMA MUNI. HOSP.	10	0	7	0	0	0	0	0	0	3
○	360003 TOKUSHIMA UNIV.	20	0	16	0	0	1	0	0	0	3
	360005 TOKUSHIMA PREF. CENTRAL HOSP.	5	0	0	0	0	2	0	0	0	3
○	370001 TAKAMATSU RED CROSS HOSP.	16	0	14	0	0	0	0	0	0	2
○	370002 TAKAMATSU MUNI. HOSP.	7	0	7	0	0	0	0	0	0	0
○	380001 SHIKOKU CANCER CENTER	60	0	49	0	0	7	0	0	1	3
	380002 EHIME PREF. CENTRAL HOSP.	3	3	0	0	0	0	0	0	0	0
○	380005 MATSUYAMA RED CROSS HOSP.	7	0	5	0	0	1	0	0	0	1
○	380006 EHIME UNIV.	33	0	23	1	0	5	1	1	0	2
○	390003 KOCHI HEALTH SCIENCE CENTER	13	0	10	0	0	3	0	0	0	0
○	390006 KOCHI UNIV.	10	0	9	0	0	1	0	0	0	0
	400008 UNIV. OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH	16	0	7	0	0	6	1	0	1	1
○	400010 KYUSHU MED. CENTER	10	0	9	0	0	1	0	0	0	0
○	400012 KYUSHU UNIV.	54	0	35	2	0	8	0	0	0	9
○	400013 FUKUOKA UNIV.	29	0	20	0	0	7	2	0	0	0
○	400014 FUKUOKA RED CROSS HOSP.	11	0	6	0	0	2	0	1	0	2
○	400017 IIZUKA HOSP.	27	0	18	0	0	6	0	0	0	3
○	400020 KURUME UNIV.	30	0	23	0	0	6	0	0	0	1
	400026 SAISEIKAI FUKUOKA GENERAL HOSP.	30	0	18	1	0	3	0	0	0	8
○	400040 KYUSHU CANCER CENTER	48	0	38	2	0	6	1	0	0	1
○	410005 SAGA UNIV.	30	0	21	0	0	6	0	0	0	3
○	420001 NAGASAKI HARBOR MED. CENTER CITY HOSP.	20	0	11	2	0	6	1	0	0	0
○	420002 NAGASAKI UNIV.	17	0	10	0	0	5	0	1	0	1
○	420003 RED CROSS NAGASAKI ATOMIC BOMB SURVIVORS HOSP.	10	0	7	0	0	3	0	0	0	0
○	420006 SASEBO KYOSAI HOSP.	21	0	17	2	0	1	0	0	0	1
○	430001 KUMAMOTO MED. CENTER	41	0	28	1	0	11	0	0	1	0
	430002 KUMAMOTO UNIV.	45	0	28	1	0	5	0	0	0	11
○	430003 KUMAMOTO CITY HOSP.	21	0	15	1	0	2	1	0	0	2
○	440002 OITA PREF. HOSP.	36	0	24	2	0	4	1	0	0	5
	440003 BEPPU MED. CENTER	18	18	0	0	0	0	0	0	0	0
○	440005 OITA UNIV.	15	0	11	2	0	1	0	0	0	1
	450001 MIYAZAKI PREF. HOSP.	28	0	12	0	0	8	0	0	0	8
○	450005 MIYAZAKI UNIV.	17	0	16	0	0	1	0	0	0	0
	460001 KAGOSHIMA UNIV.	26	26	0	0	0	0	0	0	0	0
	460004 KAGOSHIMA CITY HOSP.	36	0	21	0	0	3	0	0	1	11
○	470008 RYUKYU UNIV.	33	0	26	0	0	6	1	0	0	0
○	470010 OKINAWA PREF. CHUBU HOSP.	16	0	11	0	0	2	0	0	0	3
	Total	5,408	400	3,559	113	0	639	41	34	28	594

Table 1. No. of Patients by Stage and Age

FIGO Stage		Age		~19		20~29		30~39		40~49		50~59		60~69		70~79		80~		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I	A	0	0.0	21	0.5	88	2.1	166	4.0	284	6.8	129	3.1	66	1.6	19	0.5	773	18.6		
	B	0	0.0	6	0.1	55	1.3	150	3.6	496	11.9	377	9.1	187	4.5	44	1.1	1,315	31.6		
	C	0	0.0	2	0.0	10	0.2	25	0.6	149	3.6	193	4.6	123	3.0	35	0.8	537	12.9		
	not cl.	0	0.0	0	0.0	1	0.0	1	0.0	0	0.0	1	0.0	2	0.0	0	0.0	5	0.1		
	total	0	0.0	29	0.7	154	3.7	342	8.2	929	22.3	700	16.8	378	9.1	98	2.4	2,630	63.2		
II	A	0	0.0	1	0.0	12	0.3	18	0.4	45	1.1	48	1.2	21	0.5	7	0.2	152	3.7		
	B	0	0.0	0	0.0	11	0.3	41	1.0	59	1.4	54	1.3	31	0.7	17	0.4	213	5.1		
	not cl.	0	0.0	0	0.0	0	0.0	2	0.0	0	0.0	2	0.0	1	0.0	1	0.0	6	0.1		
	total	0	0.0	1	0.0	23	0.6	61	1.5	104	2.5	104	2.5	53	1.3	25	0.6	371	8.9		
	III	A	0	0.0	2	0.0	27	0.6	69	1.7	180	4.3	112	2.7	69	1.7	17	0.4	476	11.4	
B		0	0.0	0	0.0	0	0.0	1	0.0	4	0.1	8	0.2	3	0.1	2	0.0	18	0.4		
C		0	0.0	0	0.0	20	0.5	44	1.1	144	3.5	99	2.4	47	1.1	10	0.2	364	8.8		
not cl.		0	0.0	0	0.0	0	0.0	0	0.0	3	0.1	1	0.0	9	0.2	1	0.0	14	0.3		
total		0	0.0	2	0.0	47	1.1	114	2.7	331	8.0	220	5.3	128	3.1	30	0.7	872	21.0		
IV	A	0	0.0	0	0.0	0	0.0	1	0.0	8	0.2	5	0.1	6	0.1	0	0.0	20	0.5		
	B	0	0.0	1	0.0	7	0.2	22	0.5	80	1.9	89	2.1	43	1.0	12	0.3	254	6.1		
	not cl.	0	0.0	0	0.0	0	0.0	1	0.0	5	0.1	5	0.1	1	0.0	0	0.0	12	0.3		
	total	0	0.0	1	0.0	7	0.2	24	0.6	93	2.2	99	2.4	50	1.2	12	0.3	286	6.9		
	Total	0	0.0	33	0.8	231	5.6	541	13.0	1,457	35.0	1,123	27.0	609	14.6	165	4.0	4,159			

Table 2. No. of Patients by Treatment Method

FIGO Stage		Treatment		Surgery								Radiation				Chem.Immun. Hormon		Other		Total	
				(alone)		Radiation		Radiation Chem.Immun. Hormon		Chem.Immun. Hormon		(alone)		Chem.Immun. Hormon							
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I	A	671	16.1	3	0.1	1	0.0	63	1.5	10	0.2	0	0.0	25	0.6	0	0.0	773	18.6		
	B	1,036	24.9	4	0.1	3	0.1	258	6.2	9	0.2	1	0.0	3	0.1	1	0.0	1,315	31.6		
	C	164	3.9	23	0.6	3	0.1	342	8.2	2	0.0	0	0.0	1	0.0	2	0.0	537	12.9		
	not cl.	3	0.1	0	0.0	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	5	0.1		
	total	1,874	45.1	30	0.7	7	0.2	664	16.0	22	0.5	1	0.0	29	0.7	3	0.1	2,630	63.2		
II	A	65	1.6	3	0.1	0	0.0	82	2.0	1	0.0	0	0.0	1	0.0	0	0.0	152	3.7		
	B	58	1.4	13	0.3	1	0.0	139	3.3	2	0.0	0	0.0	0	0.0	0	0.0	213	5.1		
	not cl.	0	0.0	0	0.0	0	0.0	1	0.0	4	0.1	0	0.0	1	0.0	0	0.0	6	0.1		
	total	123	3.0	16	0.4	1	0.0	222	5.3	7	0.2	0	0.0	2	0.0	0	0.0	371	8.9		
	III	A	96	2.3	4	0.1	7	0.2	367	8.8	1	0.0	0	0.0	1	0.0	0	0.0	476	11.4	
B		4	0.1	0	0.0	0	0.0	12	0.3	0	0.0	1	0.0	0	0.0	1	0.0	18	0.4		
C		24	0.6	7	0.2	17	0.4	310	7.5	3	0.1	2	0.0	1	0.0	0	0.0	364	8.8		
not cl.		1	0.0	0	0.0	3	0.1	3	0.1	3	0.1	0	0.0	2	0.0	2	0.0	14	0.3		
total		125	3.0	11	0.3	27	0.6	692	16.6	7	0.2	3	0.1	4	0.1	3	0.1	872	21.0		
IV	A	3	0.1	0	0.0	2	0.0	11	0.3	0	0.0	0	0.0	3	0.1	1	0.0	20	0.5		
	B	14	0.3	3	0.1	9	0.2	165	4.0	3	0.1	6	0.1	47	1.1	7	0.2	254	6.1		
	not cl.	1	0.0	0	0.0	0	0.0	5	0.1	0	0.0	0	0.0	6	0.1	0	0.0	12	0.3		
	total	18	0.4	3	0.1	11	0.3	181	4.4	3	0.1	6	0.1	56	1.3	8	0.2	286	6.9		
	Total	2,140	51.5	60	1.4	46	1.1	1,759	42.3	39	0.9	10	0.2	91	2.2	14	0.3	4,159			

Table 3. No. of Patients by Histological Type

Histological Type		Endometrioid								Serous		Clear cell		Mucinous		Squamous		Mixed	
		Grade1		Grade2		Grade3		unknown											
FIGO Stage		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I	A	584	14.0	89	2.1	31	0.7	18	0.4	10	0.2	14	0.3	5	0.1	0	0.0	7	0.2
	B	746	17.9	322	7.7	120	2.9	9	0.2	22	0.5	19	0.5	3	0.1	3	0.1	19	0.5
	C	226	5.4	145	3.5	87	2.1	2	0.0	12	0.3	11	0.3	3	0.1	0	0.0	11	0.3
	not cl.	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	total	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
II	A	83	2.0	42	1.0	6	0.1	3	0.1	7	0.2	5	0.1	0	0.0	0	0.0	2	0.0
	B	79	1.9	62	1.5	32	0.8	5	0.1	8	0.2	3	0.1	2	0.0	0	0.0	5	0.1
	not cl.	1	0.0	1	0.0	0	0.0	2	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	total	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	III	A	195	4.7	106	2.5	62	1.5	9	0.2	26	0.6	12	0.3	2	0.0	0	0.0	21
B		5	0.1	4	0.1	3	0.1	1	0.0	1	0.0	1	0.0	0	0.0	0	0.0	1	0.0
C		91	2.2	87	2.1	75	1.8	10	0.2	28	0.7	18	0.4	2	0.0	0	0.0	11	0.3
not cl.		2	0.0	4	0.1	0	0.0	1	0.0	0	0.0	2	0.0	0	0.0	0	0.0	1	0.0
total		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
IV	A	4	0.1	3	0.1	5	0.1	3	0.1	2	0.0	1	0.0	0	0.0	0	0.0	0	0.0
	B	28	0.7	44	1.1	43	1.0	8	0.2	49	1.2	9	0.2	2	0.0	0	0.0	8	0.2
	not cl.	1	0.0	2	0.0	1	0.0	2	0.0	2	0.0	1	0.0	0	0.0	0	0.0	0	0.0
	total	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Total	2,046	49.2	911	21.9	465	11.2	74	1.8	167	4.0	96	2.3	19	0.5	3	0.1	86	2.1

Histological Type		Undifferentiated		Carcinofibroma		Carcinosarcoma		Unknown		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%
I	A	0	0.0	0	0.0	11	0.3	4	0.1	773	18.6
	B	1	0.0	1	0.0	45	1.1	5	0.1	1,315	31.6
	C	4	0.1	1	0.0	31	0.7	4	0.1	537	12.9
	not cl.	0	0.0	0	0.0	0	0.0	3	0.1	5	0.1
	total	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
II	A	1	0.0	0	0.0	3	0.1	0	0.0	152	3.7
	B	1	0.0	0	0.0	15	0.4	1	0.0	213	5.1
	not cl.	0	0.0	0	0.0	0	0.0	2	0.0	6	0.1
	total	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	III	A	3	0.1	0	0.0	38	0.9	2	0.0	476
B		1	0.0	0	0.0	0	0.0	1	0.0	18	0.4
C		4	0.1	1	0.0	31	0.7	6	0.1	364	8.8
not cl.		0	0.0	0	0.0	2	0.0	2	0.0	14	0.3
total		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
IV	A	1	0.0	0	0.0	1	0.0	0	0.0	20	0.5
	B	12	0.3	0	0.0	33	0.8	18	0.4	254	6.1
	not cl.	1	0.0	0	0.0	0	0.0	2	0.0	12	0.3
	total	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Total	29	0.7	3	0.1	210	5.0	50	1.2	4,159	

Table 4. 5-Year Results, Treatment Started in 2008

5-year result	No. of patients	%
Alive with no evidence of the disease	3,100	74.5
Alive with carcinoma	99	2.4
Alive with or without carcinoma unknown	0	0.0
Died of carcinoma	548	13.2
Died of other malignant tumor	37	0.9
Died of intercurrent disease	31	0.7
Cause of death unknown	26	0.6
Lost to follow-up	318	7.6
Total	4,159	

Table 5. 5-Year Survival by Stage, Treatment Started in 2008

FIGO Stage		Patients treated		5-year survival		Lost to follow-up
		No.		%		
I	A	773	2,630	96.4	94.5	220/2630(8.4%)
	B	1,315		94.3		
	C	537		92.3		
	not cl.	5		75.0		
II	A	152	371	94.5	90.3	27/371(7.3%)
	B	213		88.0		
	not cl.	6		62.5		
III	A	476	872	81.2	74.2	55/872(6.3%)
	B	18		43.2		
	C	364		67.3		
	not cl.	14		57.1		
IV	A	20	286	36.8	24.0	16/286(5.6%)
	B	254		23.5		
	not cl.	12		10.2		
Total		4,159				

Table 6. 5-Year Survival by Histological Type, Treatment Started in 2008

Histology Type	Patients treated		5-year survival	Lost to follow-up
	No.	%	%	
Endometrioid G1	2,046	49.2	94.6	149/2046(7.3%)
Endometrioid G2	911	21.9	88.2	78/911(8.6%)
Endometrioid G3	465	11.2	80.2	29/465(6.2%)
Serous	167	4.0	49.5	11/167(6.6%)
Clear	96	2.3	64.1	9/96(9.4%)
Carcinosarcoma	210	5.0	53.6	17/210(8.1%)
Other	264	6.3	64.6	25/264(9.5%)
Total	4,159			


Table 7. 5-Year Survival by Stage and Histological Type, Treatment Started in 2008

FIGO Stage	Histology Type	Patients treated		5-year survival	Lost to follow-up
		No.	%	%	
I	Endometrioid G1	1,557	59.2	97.0	7/4(175.0%)
	Endometrioid G2	556	21.1	94.8	3/4(75.0%)
	Endometrioid G3	238	9.0	94.7	1/4(25.0%)
	Serous	44	1.7	76.4	0/4(0.0%)
	Clear	44	1.7	90.3	13/4(325.0%)
	Carcinosarcoma	87	3.3	64.9	0/4(0.0%)
	Other	104	4.0	87.9	2/4(50.0%)
II	Endometrioid G1	163	43.9	97.4	2/8(25.0%)
	Endometrioid G2	105	28.3	91.1	0/8(0.0%)
	Endometrioid G3	38	10.2	86.0	0/8(0.0%)
	Serous	15	4.0	58.7	1/8(12.5%)
	Clear	8	2.2	71.4	4/8(50.0%)
	Carcinosarcoma	18	4.9	81.9	0/8(0.0%)
	Other	24	6.5	76.6	1/8(12.5%)
III	Endometrioid G1	293	33.6	86.2	0/5(0.0%)
	Endometrioid G2	201	23.1	79.2	2/5(40.0%)
	Endometrioid G3	140	16.1	73.1	0/5(0.0%)
	Serous	55	6.3	60.1	1/5(20.0%)
	Clear	33	3.8	43.2	1/5(20.0%)
	Carcinosarcoma	71	8.1	49.9	0/5(0.0%)
	Other	79	9.1	61.9	1/5(20.0%)
IV	Endometrioid G1	33	11.5	40.1	0/11(0.0%)
	Endometrioid G2	49	17.1	40.5	1/11(9.1%)
	Endometrioid G3	49	17.1	24.6	2/11(18.2%)
	Serous	53	18.5	15.2	0/11(0.0%)
	Clear	11	3.8	9.1	1/11(9.1%)
	Carcinosarcoma	34	11.9	14.2	0/11(0.0%)
	Other	57	19.9	17.7	0/11(0.0%)

Table 8. 5-Year Survival by TNM Classification, Treatment Started in 2008

TNM Stage			Patients treated		5-year survival	Lost to follow-up
			No.	%	%	
T1a	N0	M0	766	18.7	96.6	58/766(7.6%)
T1b	N0	M0	1,349	32.9	93.9	105/1349(7.8%)
T1c	N0	M0	547	13.3	91.1	55/547(10.1%)
T2a	N0	M0	155	3.8	95.2	10/155(6.5%)
T2b	N0	M0	209	5.1	87.3	15/209(7.2%)
T3a	N0	M0	366	8.9	83.1	24/366(6.6%)
T3b	N0	M0	13	0.3	53.8	0/13(0.0%)
T3c	N0	M0	26	0.6	70.6	2/26(7.7%)
T4	N0	M0	11	0.3	54.5	0/11(0.0%)
T1a	N1	M0	7	0.2	42.9	0/7(0.0%)
T1b	N1	M0	35	0.9	91.1	2/35(5.7%)
T1c	N1	M0	66	1.6	78.2	4/66(6.1%)
T2a	N1	M0	17	0.4	73.1	2/17(11.8%)
T2b	N1	M0	45	1.1	75.8	5/45(11.1%)
T3a	N1	M0	110	2.7	66.2	8/110(7.3%)
T3b	N1	M0	12	0.3	36.4	1/12(8.3%)
T3c	N1	M0	83	2.0	56.9	6/83(7.2%)
T4	N1	M0	12	0.3	16.7	0/12(0.0%)
Any T	Any N	M1	272	6.6	25.7	17/272(6.3%)


Figure 1.
Kaplan-Meier Estimated Overall Survival Curves of Corpus Cancer Patients by FIGO Stage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	1694.0431	3	<.0001
Wilcoxon	1674.7222	3	<.0001
-2Log (LR)	888.5075	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	223.6000	<.0001	<.0001
I	III	337.6000	<.0001	<.0001
I	IV	1049.1000	<.0001	<.0001
II	III	87.7831	<.0001	<.0001
II	IV	517.6000	<.0001	<.0001
III	IV	47.2838	<.0001	<.0001


Figure 2.
Kaplan-Meier Estimated Overall Survival Curves of Corpus Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	692.6164	6	<.0001
Wilcoxon	693.8816	6	<.0001
-2Log (LR)	545.0430	6	<.0001

Adjustment for Multiple Comparison for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Endometrioid G1	Endometrioid G2	82.4522	<.0001	<.0001
Endometrioid G1	Endometrioid G3	198.5000	<.0001	<.0001
Endometrioid G1	Serous	388.3000	<.0001	<.0001
Endometrioid G1	Clear	292.3000	<.0001	<.0001
Endometrioid G1	Carcinosarcoma	378.8000	<.0001	<.0001
Endometrioid G1	Other	339.5000	<.0001	<.0001
Endometrioid G2	Endometrioid G3	15.5041	<.0001	0.0016
Endometrioid G2	Serous	61.5191	<.0001	<.0001
Endometrioid G2	Clear	17.4898	<.0001	0.0006
Endometrioid G2	Carcinosarcoma	63.3607	<.0001	<.0001
Endometrioid G2	Other	52.5029	<.0001	<.0001
Endometrioid G3	Serous	15.1240	0.0001	0.0019
Endometrioid G3	Clear	0.9498	0.3298	0.9595
Endometrioid G3	Carcinosarcoma	17.2777	<.0001	0.0006
Endometrioid G3	Other	11.7066	0.0006	0.0111
Serous	Clear	60.2152	<.0001	<.0001
Serous	Carcinosarcoma	0.3298	0.5658	0.9975
Serous	Other	0.0541	0.8160	1.0000
Clear	Carcinosarcoma	61.3158	<.0001	<.0001
Clear	Other	40.3901	<.0001	<.0001
Carcinosarcoma	Other	0.5279	0.4675	0.9910


Figure 3.
Kaplan-Meier Estimated Overall Survival Curves of Corpus Cancer Patients by FIGO Stage I Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	10.1965	2	0.0061
Wilcoxon	10.1214	2	0.0063
-2Log (LR)	9.9417	2	0.0069

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
IA	IB	1.5507	0.2130	0.4265
IA	IC	9.9655	0.0016	0.0045
IB	IC	2.0441	0.1528	0.3256


Figure 4.
Kaplan-Meier Estimated Overall Survival Curves of Stage I Corpus Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	228.2334	6	<.0001
Wilcoxon	235.7515	6	<.0001
-2Log (LR)	113.7298	6	<.0001


Adjustment for Multiple Comparison for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Endometrioid G1	Endometrioid G2	14.1076	0.0002	0.0033
Endometrioid G1	Endometrioid G3	24.3612	<.0001	<.0001
Endometrioid G1	Serous	58.3458	<.0001	<.0001
Endometrioid G1	Clear	40.4399	<.0001	<.0001
Endometrioid G1	Carcinosarcoma	94.4553	<.0001	<.0001
Endometrioid G1	Other	42.1439	<.0001	<.0001
Endometrioid G2	Endometrioid G3	0.1436	0.7047	0.9998
Endometrioid G2	Serous	4.5102	0.0337	0.3385
Endometrioid G2	Clear	0.4616	0.4969	0.9937
Endometrioid G2	Carcinosarcoma	24.8189	<.0001	<.0001
Endometrioid G2	Other	1.7951	0.1803	0.8332
Endometrioid G3	Serous	5.0707	0.0243	0.2679
Endometrioid G3	Clear	0.0830	0.7733	1.0000
Endometrioid G3	Carcinosarcoma	36.4918	<.0001	<.0001
Endometrioid G3	Other	1.4057	0.2358	0.8998
Serous	Clear	12.4782	0.0004	0.0075
Serous	Carcinosarcoma	44.7277	<.0001	<.0001
Serous	Other	1.6606	0.1975	0.8574
Clear	Carcinosarcoma	88.0604	<.0001	<.0001
Clear	Other	2.0058	0.1567	0.7933
Carcinosarcoma	Other	41.3636	<.0001	<.0001

Figure 5.
Kaplan-Meier Estimated Overall Survival Curves of Corpus Cancer Patients by
FIGO Stage II Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	3.6828	1	0.0550
Wilcoxon	3.9750	1	0.0462
-2Log (LR)	3.8892	1	0.0486


Figure 6.
Kaplan-Meier Estimated Overall Survival Curves of Stage II Corpus Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	P>Chi-Square
Log-rank	34.4065	6	<.0001
Wilcoxon	32.8512	6	<.0001
-2Log (LR)	27.3230	6	0.0001

Adjustment for Multiple Comparison for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Endometrioid G1	Endometrioid G2	5.3418	0.0208	0.2384
Endometrioid G1	Endometrioid G3	13.4940	0.0002	0.0045
Endometrioid G1	Serous	24.8110	<.0001	<.0001
Endometrioid G1	Clear	16.4392	<.0001	0.0010
Endometrioid G1	Carcinosarcoma	15.1191	0.0001	0.0019
Endometrioid G1	Other	14.2478	0.0002	0.0030
Endometrioid G2	Endometrioid G3	0.5491	0.4587	0.9900
Endometrioid G2	Serous	2.5909	0.1075	0.6761
Endometrioid G2	Clear	0.1919	0.6613	0.9995
Endometrioid G2	Carcinosarcoma	0.2524	0.6154	0.9988
Endometrioid G2	Other	0.1885	0.6642	0.9995
Endometrioid G3	Serous	1.1043	0.2933	0.9420
Endometrioid G3	Clear	0.4434	0.5055	0.9944
Endometrioid G3	Carcinosarcoma	0.2296	0.6318	0.9991
Endometrioid G3	Other	0.3063	0.5799	0.9980
Serous	Clear	6.4747	0.0109	0.1436
Serous	Carcinosarcoma	4.0076	0.0453	0.4133
Serous	Other	4.1931	0.0406	0.3844
Clear	Carcinosarcoma	0.0349	0.8517	1.0000
Clear	Other	0.0033	0.9540	1.0000
Carcinosarcoma	Other	0.0114	0.9151	1.0000


Figure 7.
Kaplan-Meier Estimated Overall Survival Curves of Corpus Cancer Patients by
FIGO Stage III Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	35.4974	2	<.0001
Wilcoxon	36.1044	2	<.0001
-2Log (LR)	32.2301	2	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
III A	IIIB	33.1003	<.0001	<.0001
III A	IIIC	23.3794	<.0001	<.0001
IIIB	IIIC	10.6592	0.0011	0.0031


Figure 8.
Kaplan-Meier Estimated Overall Survival Curves of Stage III Corpus Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	74.9008	6	<.0001
Wilcoxon	73.6331	6	<.0001
-2Log (LR)	70.3924	6	<.0001


Adjustment for Multiple Comparison for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Endometrioid G1	Endometrioid G2	6.7656	0.0093	0.1255
Endometrioid G1	Endometrioid G3	18.8235	<.0001	0.0003
Endometrioid G1	Serous	34.3533	<.0001	<.0001
Endometrioid G1	Clear	41.639	<.0001	<.0001
Endometrioid G1	Carcinosarcoma	44.536	<.0001	<.0001
Endometrioid G1	Other	36.3855	<.0001	<.0001
Endometrioid G2	Endometrioid G3	2.7519	0.0971	0.6437
Endometrioid G2	Serous	7.3217	0.0068	0.0967
Endometrioid G2	Clear	9.3139	0.0023	0.0369
Endometrioid G2	Carcinosarcoma	13.6497	0.0002	0.0041
Endometrioid G2	Other	9.2235	0.0024	0.0385
Endometrioid G3	Serous	0.5920	0.4416	0.9878
Endometrioid G3	Clear	0.9245	0.3363	0.9621
Endometrioid G3	Carcinosarcoma	3.6915	0.0547	0.4660
Endometrioid G3	Other	1.4959	0.2213	0.8854
Serous	Clear	0.0247	0.8750	1.0000
Serous	Carcinosarcoma	2.3736	0.1234	0.7201
Serous	Other	0.4042	0.5249	0.9956
Clear	Carcinosarcoma	2.6629	0.1027	0.6616
Clear	Other	0.3423	0.5585	0.9972
Carcinosarcoma	Other	0.6969	0.4038	0.9814

Figure 9.
Kaplan-Meier Estimated Overall Survival Curves of Corpus Cancer Patients by
FIGO Stage IV Substage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	0.5210	1	0.4704
Wilcoxon	0.1095	1	0.7407
-2Log (LR)	0.8766	1	0.3491

Figure 10.
Kaplan-Meier Estimated Overall Survival Curves of Stage IV Corpus Cancer Patients by
Histological Type, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	24.3310	6	0.0005
Wilcoxon	31.7879	6	<.0001
-2Log (LR)	29.2705	6	<.0001

Adjustment for Multiple Comparison for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Endometrioid G1	Endometrioid G2	0.0002	0.9892	1.0000
Endometrioid G1	Endometrioid G3	1.5285	0.2163	0.8801
Endometrioid G1	Serous	6.5408	0.0105	0.1393
Endometrioid G1	Clear	8.0420	0.0046	0.0686
Endometrioid G1	Carcinosarcoma	6.0544	0.0139	0.1739
Endometrioid G1	Other	15.5544	<.0001	0.0016
Endometrioid G2	Endometrioid G3	1.3180	0.2510	0.9131
Endometrioid G2	Serous	5.5631	0.0183	0.2164
Endometrioid G2	Clear	6.4642	0.0110	0.1443
Endometrioid G2	Carcinosarcoma	5.0810	0.0242	0.2667
Endometrioid G2	Other	13.0653	0.0003	0.0056
Endometrioid G3	Serous	1.4296	0.2318	0.8961
Endometrioid G3	Clear	0.9295	0.3350	0.9616
Endometrioid G3	Carcinosarcoma	0.9022	0.3422	0.9643
Endometrioid G3	Other	5.7190	0.0168	0.2020
Serous	Clear	0.4708	0.4926	0.9934
Serous	Carcinosarcoma	0.1597	0.6895	0.9997
Serous	Other	1.3048	0.2533	0.9150
Clear	Carcinosarcoma	0.0542	0.8159	1.0000
Clear	Other	5.6329	0.0176	0.2099
Carcinosarcoma	Other	2.9717	0.0847	0.5999

卵巣悪性腫瘍治療成績

Statement for the Year 2008, Inclusive, Malignant Ovarian Tumor

Table A. 5-Year Results, Stage I-IV

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
○	010003 HOKKAIDO CANCER CENTER	30	0	12	1	0	15	0	0	0	2
	010024 NTT EAST JAPAN SAPPORO HOSP.	12	0	8	0	0	0	0	0	0	4
○	010025 SAPPORO MED. UNIV.	33	0	23	0	0	4	0	0	0	6
○	010027 HOKKAIDO UNIV.	13	0	8	0	0	5	0	0	0	0
○	010028 KKR SAPPORO MED. CENTER	11	0	6	0	0	5	0	0	0	0
	010037 ASAHIKAWA-KOSEI GENERAL HOSP.	12	12	0	0	0	0	0	0	0	0
○	010038 ASAHIKAWA MED. UNIV.	19	0	11	0	0	6	0	0	0	2
○	010040 ASAHIKAWA MED. COLL.	18	0	8	1	0	7	0	0	0	2
	020004 AOMORI PREF. CENTRAL HOSP.	16	16	0	0	0	0	0	0	0	0
○	020008 MUTSU GENERAL HOSP.	3	0	2	0	0	1	0	0	0	0
○	020012 HIROSAKI UNIV.	14	0	7	1	0	4	0	0	0	2
○	020017 MISAWA CITY HOSP.	6	0	3	0	0	3	0	0	0	0
	030004 IWATE MED. UNIV.	1	1	0	0	0	0	0	0	0	0
○	040004 TOHOKU UNIV.	41	0	19	5	0	17	0	0	0	0
	040008 MIYAGI CANCER CENTER	25	0	9	3	0	6	0	0	1	6
	040013 SENDAI MED. CENTER	21	17	0	0	0	3	0	0	0	1
○	050001 AKITA RED CROSS HOSP.	5	0	2	1	0	2	0	0	0	0
	050003 AKITA UNIV.	17	0	8	0	0	3	1	0	0	5
○	060002 YAMAGATA PREF. CENTRAL HOSP.	12	0	7	2	0	3	0	0	0	0
○	060005 YAMAGATA UNIV.	23	0	14	0	0	8	0	0	0	1
○	080001 TSUCHIURA KYODO GENERAL HOSP.	9	0	5	0	0	4	0	0	0	0
○	080006 TSUKUBA GAKUEN HOSP.	2	0	2	0	0	0	0	0	0	0
○	080007 TSUKUBA UNIV.	38	1	22	4	0	11	0	0	0	0
	080021 HITACHI GENERAL HOSP.	9	9	0	0	0	0	0	0	0	0
○	080031 TSUKUBA MED. CENTER	2	0	1	0	0	1	0	0	0	0
	090001 TOCHIGI MED. CENTER	3	0	1	0	0	1	0	0	0	1
○	090004 DOKKYO MED. UNIV.	30	0	14	1	0	11	0	1	0	3
○	090005 SAISEIKAI UTSUNOMIYA HOSP.	16	0	8	0	0	5	0	0	0	3
○	090011 ASHIKAGA RED CROSS HOSP.	14	0	6	0	0	6	0	0	0	2
○	090015 JICHI MED. UNIV.	43	0	23	1	0	12	0	0	0	7
○	090016 TOCHIGI CANCER CENTER	20	0	16	0	0	4	0	0	0	0
○	100012 GUNMA UNIV.	7	0	4	0	0	3	0	0	0	0
○	110008 SAITAMA MED. CENTER	7	0	3	1	0	2	0	1	0	0
○	110014 KOSHIGAYA MUNI. HOSP.	18	0	12	0	0	6	0	0	0	0
○	110023 SAITAMA NATIONAL HOSP.	5	0	2	1	0	2	0	0	0	0
	110027 NATIONAL DEFENSE MED. COLL.	24	24	0	0	0	0	0	0	0	0
○	110030 SAITAMA CANCER CENTER	27	0	17	2	0	8	0	0	0	0
○	110055 SAITAMA INTERNATIONAL MED. CENTER	42	0	21	5	0	11	0	0	0	5
○	120005 CHIBA UNIV.	29	0	17	2	0	10	0	0	0	0
	120009 NIPPON MED. SCH. CHIBA HOKUSOU HOSP.	8	8	0	0	0	0	0	0	0	0
○	120012 MATSUDO CITY HOSP.	10	0	6	0	0	4	0	0	0	0
○	120015 TOKYO DENTAL COLL. ICHIKAWA GENERAL HOSP.	14	0	4	0	0	10	0	0	0	0
	120021 JIKEI UNIV. KASHIWA HOSP.	59	59	0	0	0	0	0	0	0	0
○	120023 JUNTENDO UNIV. URAYASU HOSP.	27	0	5	2	0	17	0	0	0	3
○	120025 TOHO UNIV. SAKURA MED. CENTER	13	0	7	0	0	4	0	0	0	2
	120029 ASAHI CENTRAL HOSP.	32	32	0	0	0	0	0	0	0	0
○	120035 KAMEDA MED. CENTER	16	0	6	3	0	4	0	0	0	3
○	120042 CHIBA CANCER CENTER	18	0	12	1	0	5	0	0	0	0
○	130005 MITSUI MEMORIAL HOSP.	12	0	7	2	0	3	0	0	0	0
○	130009 NATIONAL CANCER CENTER	40	0	21	5	0	10	0	0	0	4
○	130013 JIKEI UNIV.	42	0	20	2	0	12	0	0	0	8
○	130023 JUNTENDO UNIV.	32	0	13	1	0	13	1	1	0	3
	130024 TOKYO MED. DENT. UNIV.	15	15	0	0	0	0	0	0	0	0
○	130025 NIPPON MED. SCH.	13	0	4	4	0	3	0	0	0	2

	A	B	C	D	E	F	G	H	I	J	K		
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up		
○	130026	TOKYO UNIV.	39	0	21	5	0	8	0	2	0	3	
○	130029	TOKYO WOMENS MED. UNIV. MED. CENTER EAST	12	0	8	3	0	1	0	0	0	0	
	130034	JIKEI UNIV. KATSUSHIKA MED. CENTER	24	24	0	0	0	0	0	0	0	0	
	130038	TOKYO METRO. BOKUTOH HOSP.	18	18	0	0	0	0	0	0	0	0	
○	130044	NTT MED. CENTER TOKYO	16	0	7	1	0	7	0	0	0	1	
	130046	SHOWA UNIV.	19	0	9	1	0	5	0	0	0	4	
○	130050	TOHO UNIV. OMORI MED. CENTER	16	0	5	2	0	7	0	1	0	1	
○	130055	RED CROSS MED. CENTER	14	0	6	0	0	6	0	0	0	2	
○	130061	TOKYO MED. CENTER	9	0	4	0	0	5	0	0	0	0	
○	130064	TOHO UNIV. OHASHI MED. CENTER	10	0	6	1	0	2	1	0	0	0	
	130074	TOKYO MED. UNIV.	27	0	6	0	0	3	0	0	0	18	
○	130077	KEIO UNIV.	43	0	27	2	0	9	0	4	1	0	4
	130080	NATIONAL CENTER FOR GLOBAL HEALTH AND MED.	15	15	0	0	0	0	0	0	0	0	
	130081	TOKYO WOMENS MED. HOSP.	16	0	9	0	0	2	0	0	0	5	
	130085	KOSEI HOSP.	10	10	0	0	0	0	0	0	0	0	
	130092	TEIKYO UNIV.	9	0	4	0	0	1	0	0	0	4	
○	130095	NIHON UNIV.	24	0	13	4	0	6	1	0	0	0	
○	130099	MUSASHINO RED CROSS HOSP.	29	0	9	8	0	9	0	0	0	3	
○	130100	KYORIN UNIV.	34	0	18	0	0	10	1	2	0	3	
○	130102	TOKYO METRO. TAMA MED. CENTER	20	0	9	0	0	7	0	0	0	4	
	130107	TACHIKAWA HOSP.	16	0	6	1	0	3	0	0	2	4	
○	130112	MACHIDA MUNI. HOSP.	9	0	6	0	0	2	0	1	0	0	
	130119	NIPPON MED. SCH. TAMA NAGAYAMA HOSP.	4	4	0	0	0	0	0	0	0	0	
○	130122	TOKYO METRO. KOMAGOME HOSP.	25	0	11	1	0	10	0	1	0	2	
	130124	KYOUNDO HOSP.	5	0	3	0	0	0	0	0	0	2	
○	130125	CANCER INST. HOSP.	81	0	39	12	0	30	0	0	0	0	
	130135	TAMA-NAMBU SHIIKI HOSP.	9	9	0	0	0	0	0	0	0	0	
	130137	TOKAI UNIV. HACHIOJI HOSP.	6	6	0	0	0	0	0	0	0	0	
	140006	NIPPON MED. SCH. MUSASHI KOSUGI HOSP.	11	0	3	0	0	4	0	0	0	4	
○	140008	KANTO ROSAI HOSP.	9	0	4	2	0	3	0	0	0	0	
○	140012	ST. MARIANNA UNIV.	30	0	14	1	0	10	0	1	0	4	
	140016	YOKOHAMA ROSAI HOSP.	6	0	3	0	0	1	0	0	0	2	
○	140017	SHOWA UNIV. FUJIGAOKA HOSP.	15	0	5	0	0	8	0	0	0	2	
○	140020	KITASATO UNIV.	38	0	21	2	0	8	0	0	0	7	
○	140029	YOKOHAMA CITY UNIV.	20	0	13	1	0	6	0	0	0	0	
○	140030	YOKOHAMA MINAMI KYOSAI HOSP.	13	0	4	2	0	5	0	0	0	2	
○	140035	YOKOHAMA MUNI. CITIZENS HOSP.	21	0	8	2	0	8	0	0	0	3	
○	140037	ST. MARIANNA UNIV. YOKOHAMA CITY SEIBU HOSP.	6	0	2	0	0	3	0	0	0	1	
	140044	SHONAN KAMAKURA GENERAL HOSP.	3	0	1	0	0	1	0	0	0	1	
	140054	ISEHARA KYODO HOSP.	4	0	2	0	0	1	0	0	0	1	
○	140055	TOKAI UNIV.	34	0	13	2	0	15	2	0	1	1	
○	140059	KANAGAWA CANCER CENTER	31	0	13	3	0	15	0	0	0	0	
○	140061	YOKOHAMA CITY UNIV. MED. CENTER	12	0	8	1	0	3	0	0	0	0	
○	150002	YAMANASHI PREF. CENTRAL HOSP.	8	0	4	2	0	2	0	0	0	0	
○	150006	UNIV. OF YAMANASHI	14	0	9	0	0	5	0	0	0	0	
	160001	NAGANO RED CROSS HOSP.	10	0	1	0	0	6	0	0	0	3	
○	160022	NAGANO MUNI. HOSP.	16	0	10	1	0	4	0	0	0	1	
	170006	FUJI CITY GENERAL HOSP.	1	1	0	0	0	0	0	0	0	0	
○	170009	SHIZUOKA RENERAL HOSP.	24	0	13	0	0	7	0	0	0	4	
○	180001	NAGAOKA RED CROSS HOSP.	14	0	8	2	0	2	0	0	0	2	
○	180010	NIIGATA CANCER CENTER HOSP.	40	0	27	1	0	11	1	0	0	0	
○	190001	TOYAMA UNIV.	7	0	3	0	0	3	0	0	0	1	
○	190002	TOYAMA RED CROSS HOSP.	7	0	2	1	0	2	1	1	0	0	
○	190009	TAKAOKA CITY HOSP.	5	0	1	1	0	2	0	0	0	1	
	200001	KANAZAWA MED. UNIV.	3	0	0	1	0	1	0	0	0	1	
○	200002	KANAZAWA MED. CENTER	5	0	2	0	0	3	0	0	0	0	
○	200004	KANAZAWA UNIV.	19	0	12	2	0	5	0	0	0	0	
○	210002	FUKUI PREF. HOSP.	12	0	7	0	0	3	0	0	0	2	
○	210004	FUKUI RED CROSS UNIV.	7	0	5	0	0	2	0	0	0	0	

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
	220002 GIFU UNIV.	22	0	6	2	0	6	0	0	0	8
○	220006 OGAKI MUNI. HOSP.	16	0	7	0	0	5	0	1	0	3
○	230001 TOYOHASHI MUNI. HOSP.	22	0	10	1	0	7	1	0	0	3
○	230014 RED CROSS NAGOYA DAIICHI HOSP.	23	0	11	2	0	10	0	0	0	0
	230031 NAGOYA UNIV.	30	30	0	0	0	0	0	0	0	0
○	230034 NAGOYA CITY UNIV.	17	0	7	1	0	6	1	0	0	2
○	230035 FUJITA HEALTH UNIV.	18	0	8	3	0	7	0	0	0	0
○	230040 AICHI MED. UNIV.	15	0	3	1	0	7	0	0	1	3
○	230052 AICHI CANCER CENTER	40	0	18	1	0	19	0	0	0	2
○	240002 MIE PREF. GENERAL MED. CENTER	8	0	2	0	0	6	0	0	0	0
	240003 YOKKAICHI MUNI. HOSP	7	0	2	2	0	1	0	0	0	2
○	240008 MIE CHUO MED. CENTER	12	0	7	1	0	4	0	0	0	0
○	240015 ISE RED CROSS HOSP.	12	0	6	1	0	3	0	0	0	2
○	250001 OHTSU RED CROSS HOSP.	9	0	6	0	0	3	0	0	0	0
	250003 SHIGA UNIV. OF MED. SCIENCE	9	9	0	0	0	0	0	0	0	0
○	250006 OMIHACHIMAN COMMUNITY MED. CENTER	3	0	0	0	0	2	1	0	0	0
○	250008 SHIGA MED. CENTER FOR ADULTS	9	0	6	1	0	2	0	0	0	0
○	260002 KYOTO 2ND RED CROSS HOSP.	21	0	9	1	0	9	0	0	0	2
○	260003 KYOTO PREF. UNIV. OF MED.	10	0	8	0	0	1	0	0	0	1
○	260007 KYOTO 1ST RED CROSS HOSP.	13	0	4	4	0	3	0	0	0	2
○	260009 KYOTO UNIV.	24	0	12	2	0	9	0	0	0	1
○	260013 KYOTO KATSURA HOSP.	10	0	4	0	0	4	0	0	0	2
	260014 KYOTO MED. CENTER	13	0	5	1	0	7	0	0	0	0
○	260017 SAISEIKAI KYOTO HOSP.	6	0	3	1	0	2	0	0	0	0
○	270003 KITANO HOSP.	26	0	19	1	0	3	0	0	0	3
	270007 OSAKA CITY GENERAL HOSP.	27	27	0	0	0	0	0	0	0	0
○	270009 OSAKA NATIONAL HOSP.	13	0	8	0	0	4	0	0	0	1
○	270013 OSAKA POLICE HOSP.	13	0	5	3	0	4	0	0	0	1
	270014 OSAKA RED CROSS HOSP.	20	20	0	0	0	0	0	0	0	0
○	270016 OSAKA CITY UNIV.	34	0	15	2	0	16	0	0	0	1
	270018 NISSAY HOSP.	3	3	0	0	0	0	0	0	0	0
○	270032 SAISEIKAI SUITA HOSP.	13	0	7	1	0	4	0	0	0	1
	270035 OSAKA UNIV.	35	0	18	1	0	6	0	0	0	10
○	270041 OSAKA MED. COLL.	18	0	10	0	0	5	0	0	0	3
○	270042 KANSAI MED. UNIV.	17	0	7	1	0	7	0	0	1	1
	270056 KINKI UNIV.	41	0	0	0	0	0	0	0	0	41
	270060 SAKAI CITY HOSP.	7	0	1	0	0	3	0	0	0	3
○	270062 OSAKA ROUSAI HOSP.	19	0	11	0	0	6	0	0	0	2
○	270101 OSAKA MED. CENTER FOR CANCER AND CARDIOVASCULAR DISEASES	24	0	16	3	0	5	0	0	0	0
○	280001 KOBE UNIV.	21	0	11	6	0	4	0	0	0	0
○	280002 KOBE CITY MED. CENTER GENERAL HOSP.	27	0	17	3	0	6	0	0	0	1
○	280010 KOBE MED. CENTER	5	0	2	0	0	2	0	0	0	1
	280012 HYOGO PREF. AWAJI MED. CENTER	5	2	0	0	0	1	0	1	0	1
○	280015 KANSAI ROUSAI HOSP.	17	0	6	1	0	7	0	0	0	3
	280021 HYOGO MED. COLL.	25	25	0	0	0	0	0	0	0	0
○	280028 TOYOOKA PUBLIC HOSP.	4	0	2	0	0	1	0	1	0	0
○	280030 HIMEJI RED CROSS HOSP.	12	0	5	1	0	5	0	0	0	1
○	280033 HYOGO CANCER CENTER	56	0	31	3	0	20	1	0	0	1
○	290003 NARA PREF. NARA HOSP.	13	0	7	0	0	5	0	1	0	0
○	290004 TENRI HOSP.	8	0	6	2	0	0	0	0	0	0
	290007 NARA MED. UNIV.	28	0	11	5	0	10	0	0	0	2
○	290019 YAMATO TAKADA MUNI. HOSP.	8	0	2	1	0	5	0	0	0	0
○	300002 JAPANESE RED CROSS WAKAYAMA MED. CENTER	22	0	3	3	0	11	1	1	0	3
	300003 WAKAYAMA MED. UNIV.	13	0	6	1	0	2	0	0	0	4
○	310001 TOTTORI PREF. CENTRAL HOSP.	9	0	4	1	0	4	0	0	0	0
○	310007 TOTTORI UNIV.	24	0	12	2	0	9	0	0	0	1
	320003 SHIMANE UNIV.	1	1	0	0	0	0	0	0	0	0
○	320004 SHIMANE PREF. CENTRAL HOSP.	8	0	3	1	0	3	0	1	0	0
	330002 JAPANESE RED CROSS OKAYAMA HOSP.	9	0	3	1	0	3	0	0	0	2

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
	330003 KAWASAKI HOSP.	3	0	1	0	0	1	0	0	0	1
○	330004 OKAYAMA SAISEIKAI GENERAL HOSP.	7	0	0	0	0	7	0	0	0	0
○	330006 OKAYAMA UNIV.	13	0	4	1	0	5	0	2	0	1
○	330007 OKAYAMA MED. CENTER	1	0	1	0	0	0	0	0	0	0
	330008 KURASHIKI CENTRAL HOSP.	19	0	3	2	0	8	2	0	0	4
○	330009 KAWASAKI MED. SCH.	6	0	4	0	0	1	0	0	0	1
○	330010 KURASHIKI MED. CENTER	15	0	11	2	0	1	0	0	0	1
○	340001 FUKUYAMA MED. CENTER	8	0	6	1	0	1	0	0	0	0
○	340007 HIROSHIMA CITY HOSP.	16	0	9	2	0	3	0	2	0	0
	340008 HIROSHIMA RED CROSS HOSP. AND ATOMIC-BOMB SURVIVORS HOSP.	6	0	1	0	0	3	0	0	0	2
○	340010 HIROSHIMA CITY ASA HOSP.	14	0	9	1	0	2	0	1	0	1
○	340012 HIROSHIMA UNIV.	7	0	2	2	0	1	0	1	0	1
○	340014 HIROSHIMA PREF. HOSP.	10	0	6	0	0	2	0	0	0	2
○	340015 KURE MED. CENTER	18	0	11	0	0	5	0	0	0	2
○	340018 HIROSHIMA GENERAL HOSP.	5	0	2	0	0	2	0	0	0	1
	350003 TOKUYAMA CENTRAL HOSP.	15	15	0	0	0	0	0	0	0	0
	350008 YAMAGUCHI RED CROSS HOSP.	4	0	3	0	0	0	0	0	0	1
○	350009 YAMAGUCHI UNIV.	8	0	5	0	0	3	0	0	0	0
	360002 TOKUSHIMA MUNI. HOSP.	2	0	0	0	0	0	1	0	0	1
○	360003 TOKUSHIMA UNIV.	9	0	6	0	0	3	0	0	0	0
○	360005 TOKUSHIMA PREF. CENTRAL HOSP.	6	0	4	0	0	1	0	0	0	1
○	370001 TAKAMATSU RED CROSS HOSP.	12	0	6	0	0	5	0	0	0	1
○	380001 SHIKOKU CANCER CENTER	29	0	15	4	0	9	0	0	0	1
	380002 EHIME PREF. CENTRAL HOSP.	10	10	0	0	0	0	0	0	0	0
○	380005 MATSUYAMA RED CROSS HOSP.	3	0	3	0	0	0	0	0	0	0
○	380006 EHIME UNIV.	19	0	8	1	0	10	0	0	0	0
○	390003 KOCHI HEALTH SCIENCE CENTER	7	0	5	0	0	1	0	0	0	1
○	390006 KOCHI UNIV.	10	0	2	2	0	5	0	0	0	1
○	400008 UNIV. OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH	18	0	8	2	0	6	0	0	0	2
○	400010 KYUSHU MED. CENTER	17	0	12	0	0	4	0	0	0	1
○	400012 KYUSHU UNIV.	35	0	21	7	0	7	0	0	0	0
○	400013 FUKUOKA UNIV.	7	0	4	1	0	2	0	0	0	0
○	400014 FUKUOKA RED CROSS HOSP.	7	0	5	0	0	2	0	0	0	0
	400017 IIZUKA HOSP.	17	0	7	3	0	3	0	0	0	4
○	400020 KURUME UNIV.	17	0	11	0	0	5	0	0	0	1
○	400026 SAISEIKAI FUKUOKA GENERAL HOSP.	25	0	12	1	0	8	0	0	0	4
○	400040 KYUSHU CANCER CENTER	37	0	21	3	0	13	0	0	0	0
○	410005 SAGA UNIV.	11	0	6	1	0	3	0	0	0	1
○	420001 NAGASAKI HARBOR MED. CENTER CITY HOSP.	14	0	6	3	0	4	0	0	0	1
○	420002 NAGASAKI UNIV.	10	0	6	0	0	3	1	0	0	0
○	420003 RED CROSS NAGASAKI ATOMIC BOMB HOSP.	5	0	3	1	0	1	0	0	0	0
○	420006 SASEBO KYOSAI HOSP.	10	0	6	1	0	1	0	0	0	2
	430001 KUMAMOTO MED. CENTER	14	0	5	1	0	3	0	0	0	5
○	430002 KUMAMOTO UNIV.	32	0	13	5	0	13	0	0	0	1
○	430003 KUMAMOTO CITY HOSP.	13	0	8	0	0	4	0	1	0	0
○	440002 OITA PREF. HOSP.	22	0	10	1	0	8	0	0	0	3
	440003 BEPPU MED. CENTER	16	16	0	0	0	0	0	0	0	0
○	440005 OITA UNIV.	7	0	2	0	0	3	0	1	0	1
	450001 MIYAZAKI PREF. HOSP.	19	0	7	3	0	5	0	0	0	4
	460001 KAGOSHIMA UNIV.	18	18	0	0	0	0	0	0	0	0
○	460004 KAGOSHIMA CITY HOSP.	31	0	17	0	0	9	0	0	0	5
○	470008 RYUKYU UNIV.	14	0	7	1	0	5	0	0	0	1
○	470010 OKINAWA PREF. CHUBU HOSP.	10	0	7	0	0	3	0	0	0	0
	Total	3,734	457	1,593	239	0	1,034	18	27	6	360

Table 1. No. of Patients by Stage and Age

FIGO Stage		Age		~19		20~29		30~39		40~49		50~59		60~69		70~79		80~		Total	
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I	A	8	0.3	17	0.6	51	1.8	99	3.5	130	4.5	88	3.1	41	1.4	17	0.6	451	15.7		
	B	0	0.0	0	0.0	3	0.1	3	0.1	3	0.1	5	0.2	3	0.1	1	0.0	18	0.6		
	C(b)	5	0.2	13	0.5	46	1.6	94	3.3	156	5.4	99	3.5	28	1.0	7	0.2	448	15.6		
	C(1)	0	0.0	0	0.0	2	0.1	4	0.1	9	0.3	5	0.2	3	0.1	1	0.0	24	0.8		
	C(2)	0	0.0	6	0.2	13	0.5	31	1.1	45	1.6	17	0.6	8	0.3	4	0.1	124	4.3		
	C(a)	0	0.0	6	0.2	24	0.8	35	1.2	43	1.5	42	1.5	6	0.2	4	0.1	160	5.6		
	total	13	0.5	42	1.5	139	4.8	266	9.3	386	13.5	256	8.9	89	3.1	34	1.2	1,225	42.7		
II	A	0	0.0	0	0.0	1	0.0	4	0.1	13	0.5	7	0.2	2	0.1	0	0.0	27	0.9		
	B	1	0.0	0	0.0	2	0.1	7	0.2	9	0.3	6	0.2	5	0.2	2	0.1	32	1.1		
	C(b)	0	0.0	1	0.0	8	0.3	11	0.4	23	0.8	16	0.6	5	0.2	4	0.1	68	2.4		
	C(1)	0	0.0	0	0.0	0	0.0	2	0.1	5	0.2	4	0.1	1	0.0	0	0.0	12	0.4		
	C(2)	0	0.0	2	0.1	5	0.2	9	0.3	21	0.7	9	0.3	10	0.3	1	0.0	57	2.0		
	C(a)	1	0.0	2	0.1	3	0.1	19	0.7	25	0.9	24	0.8	4	0.1	0	0.0	78	2.7		
	total	2	0.1	5	0.2	19	0.7	52	1.8	96	3.3	66	2.3	27	0.9	7	0.2	274	9.6		
III	A	1	0.0	2	0.1	3	0.1	5	0.2	14	0.5	4	0.1	2	0.1	0	0.0	31	1.1		
	B	3	0.1	5	0.2	15	0.5	20	0.7	19	0.7	19	0.7	24	0.8	4	0.1	109	3.8		
	C	5	0.2	8	0.3	27	0.9	114	4.0	211	7.4	193	6.7	92	3.2	19	0.7	669	23.3		
	total	9	0.3	15	0.5	45	1.6	139	4.8	244	8.5	216	7.5	118	4.1	23	0.8	809	28.2		
IV	1	0.0	4	0.1	14	0.5	36	1.3	62	2.2	69	2.4	46	1.6	2	0.1	234	8.2			
Neoadjuvant Chemotherapy	0	0.0	1	0.0	9	0.3	38	1.3	88	3.1	119	4.2	60	2.1	6	0.2	321	11.2			
Unknown	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	1	0.0	0	0.0	0	0.0	3	0.1			
Total	25	0.9	67	2.3	226	7.9	531	18.5	878	30.6	727	25.4	340	11.9	72	2.5	2,866				

Table 2. No. of Patients by Histological Type

Histological Type		Surface Epithelial/Stromal Tumors																																											
		Serous						Mucinous						Endometrioid						Clear						Undifferentiated						Mixed						Others							
		No.		%		No.		%		No.		%		No.		%		No.		%		No.		%		Adenosarcoma (Homologous)		Adenosarcoma (Heterologous)		Mesodermal mixed (Homologous)		Mesodermal mixed (Heterologous)													
FIGO Stage		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%														
I	A	52	1.8	125	4.4	103	3.6	114	4.0	1	0.0	12	0.4	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	B	6	0.2	5	0.2	3	0.1	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	C(b)	53	1.8	54	1.9	102	3.6	199	6.9	1	0.0	17	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	C(1)	1	0.0	6	0.2	4	0.1	11	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	C(2)	19	0.7	26	0.9	28	1.0	39	1.4	0	0.0	3	0.1	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0														
	C(a)	23	0.8	38	1.3	31	1.1	46	1.6	1	0.0	7	0.2	1	0.0	1	0.0	1	0.0	1	0.0	1	0.0	1	0.0	1	0.0	0	0.0	0	0.0														
	total	154	5.4	254	8.9	271	9.5	411	14.3	3	0.1	39	1.4	2	0.1	2	0.1	2	0.1	2	0.1	2	0.1	2	0.1	2	0.1	0	0.0	0	0.0														
II	A	9	0.3	1	0.0	10	0.3	3	0.1	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	B	7	0.2	0	0.0	12	0.4	3	0.1	0	0.0	1	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	C(b)	13	0.5	7	0.2	18	0.6	15	0.5	2	0.1	4	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	C(1)	5	0.2	2	0.1	5	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	C(2)	19	0.7	3	0.1	14	0.5	13	0.5	0	0.0	3	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0														
	C(a)	19	0.7	5	0.2	22	0.8	13	0.5	2	0.1	5	0.2	1	0.0	0	0.0	0	0.0	2	0.1	2	0.1	2	0.1	2	0.1	2	0.1	2	0.1														
	total	72	2.5	18	0.6	81	2.8	47	1.6	5	0.2	13	0.5	2	0.1	0	0.0	3	0.1	3	0.1	5	0.2	4	0.1	3	0.1	2	0.1	2	0.1														
III	A	14	0.5	2	0.1	5	0.2	8	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0														
	B	42	1.5	10	0.3	17	0.6	19	0.7	5	0.2	3	0.1	0	0.0	1	0.0	1	0.0	0	0.0	1	0.0	0	0.0	1	0.0	0	0.0	0	0.0														
	C	387	13.5	25	0.9	65	2.3	83	2.9	29	1.0	19	0.7	3	0.1	2	0.1	4	0.1	4	0.1	3	0.1	3	0.1	4	0.1	3	0.1	0	0.0														
	total	443	15.5	37	1.3	87	3.0	110	3.8	34	1.2	22	0.8	3	0.1	3	0.1	5	0.2	4	0.1	5	0.2	4	0.1	3	0.1	4	0.1	0	0.0														
IV	111	3.9	21	0.7	27	0.9	32	1.1	12	0.4	4	0.1	0	0.0	0	0.0	3	0.1	2	0.1	2	0.1	2	0.1	2	0.1	2	0.1	2	0.1															
Neoadjuvant Chemotherapy	205	7.2	9	0.3	23	0.8	35	1.2	7	0.2	6	0.2	1	0.0	0	0.0	3	0.1	0	0.0	3	0.1	0	0.0	0	0.0	0	0.0	0	0.0															
Unknown	1	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0															
Total	986	34.4	339	11.8	489	17.1	637	22.2	61	2.1	84	2.9	8	0.3	5	0.2	16	0.6	8	0.3	8	0.3	8	0.3	8	0.3	8	0.3	8	0.3															

Histological Type		Surface Epithelial/Stromal Tumors										Sex Cord/Stromal Tumor						Germ cell							
		Others										Srtoli-stromal (poor)						Others		Immature teratoma (G3)		Dysgerminoma			
		Stromal Sarcoma		Brenner		Transitional Cell		Unclassified		Other		No.		%		No.		%		No.		%		No.	
FIGO Stage		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I	A	0	0.0	1	0.0	2	0.1	0	0.0	3	0.1	3	0.1	1	0.0	2	0.1	5	0.2	4	0.1	0	0.0	0	0.0
	B	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(b)	0	0.0	2	0.1	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0	3	0.1	0	0.0	0	0.0
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
	C(2)	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	0.1	0	0.0
	C(a)	0	0.0	0	0.0	0	0.0	2	0.1	3	0.1	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0
	total	1	0.0	3	0.1	2	0.1	4	0.1	9	0.3	3	0.1	1	0.0	2	0.1	7	0.2	13	0.5	0	0.0	0	0.0
II	A	0	0.0	1	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	B	0	0.0	0	0.0	2	0.1	1	0.0	2	0.1	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	0	0.0	0	0.0
	C(b)	0	0.0	0	0.0	1	0.0	1	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(2)	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
	C(a)	0	0.0	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0
	total	0	0.0	2	0.1	3	0.1	2	0.1	7	0.2	1	0.0	0	0.0	0	0.0	2	0.1	2	0.1	2	0.1	2	0.1
III	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
	B	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	1	0.0	0	0.0	3	0.1	1	0.0	0	0.0	1	0.0
	C	0	0.0	1	0.0	3	0.1	4	0.1	9	0.3	0	0.0	1	0.0	0	0.0	2	0.1	2	0.1	2	0.1	2	0.1
	total	0	0.0	1	0.0	3	0.1	4	0.1	10	0.3	0	0.0	2	0.1	0	0.0	5	0.2	4	0.1	2	0.1	2	0.1
IV	1	0.0	0	0.0	1	0.0	4	0.1	4	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	
Neoadjuvant Chemotherapy	0	0.0	0	0.0	1	0.0	16	0.6	11	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	
Unknown	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	
Total	2	0.1	6	0.2	10	0.3	30	1.1	41	1.4	4	0.1	3	0.1	2	0.1	14	0.5	21	0.7	0	0.0	21	0.7	

Histological Type		Germ cell																Others					
		Yolk sac		Mixed germ cell						Mature cystic teratoma with malignant transformation		Others								Carcinosarcoma			
				Yolk sac+ Dysgerminoma		Yolk sac+ Immature teratoma		Other				Embryonal		Polyembryoma		Choriocarcinoma		Other					
FIGO Stage		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
I	A	5	0.2	0	0.0	2	0.1	0	0.0	12	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	B	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(b)	4	0.1	1	0.0	0	0.0	0	0.0	5	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(2)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(a)	1	0.0	0	0.0	0	0.0	0	0.0	3	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	total		10	0.3	1	0.0	2	0.1	0	0.0	21	0.7	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1
II	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	B	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(b)	0	0.0	0	0.0	0	0.0	0	0.0	5	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(2)	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(a)	2	0.1	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0
	total		2	0.1	0	0.0	0	0.0	0	0.0	9	0.3	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1
III	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	B	1	0.0	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C	2	0.1	1	0.0	1	0.0	0	0.0	10	0.3	0	0.0	0	0.0	1	0.0	1	0.0	1	0.0	5	0.2
	total		3	0.1	1	0.0	1	0.0	0	0.0	12	0.4	0	0.0	0	0.0	1	0.0	1	0.0	1	0.0	5
IV		1	0.0	1	0.0	1	0.0	1	0.0	1	0.0	0	0.0	0	0.0	0	0.0	1	0.0	1	0.0	2	0.1
Neoadjuvant Chemotherapy		1	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Unknown		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Total		17	0.6	3	0.1	5	0.2	1	0.0	43	1.5	0	0.0	0	0.0	1	0.0	2	0.1	9	0.3		

Histological Type		Others																Total					
		Others																					
		Rete ovarii		Small		Hepatoid		Squamous		Gestational trophoblastic		Malignant Lymphomas		Unclassified		Probable wolffian origin				Other			
FIGO Stage		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
I	A	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	451	15.7
	B	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	18	0.6
	C(b)	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	448	15.6
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	24	0.8
	C(2)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	124	4.3
	C(a)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	160	5.6
	total		0	0.0	0	0.0	0	0.0	4	0.1	0	0.0	0	0.0	0	0.0	0	0.0	3	0.1	1,225	42.7	
II	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	27	0.9
	B	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	32	1.1
	C(b)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	68	2.4
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	12	0.4
	C(2)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	57	2.0
	C(a)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	78	2.7
	total		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	274
III	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	31	1.1
	B	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	109	3.8
	C	0	0.0	1	0.0	0	0.0	3	0.1	0	0.0	0	0.0	0	0.0	0	0.0	2	0.1	0	0.0	669	23.3
total		0	0.0	1	0.0	0	0.0	4	0.1	0	0.0	0	0.0	0	0.0	0	0.0	3	0.1	809	28.2		
IV		0	0.0	1	0.0	0	0.0	2	0.1	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	234	8.2
Neoadjuvant Chemotherapy		0	0.0	0	0.0	0	0.0	1	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	321	11.2
Unknown		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.1
Total		0	0	2	0.1	0	0	11	0.4	0	0	0	0	0	0	0	0	6	0.2	2,866			

Table 3. 5-Year Results, Treatment Started in 2008

5-year result	No. of patients	%
Alive with no evidence of the disease	1,457	50.8
Alive with carcinoma	217	7.6
Alive with or without carcinoma unknown	0	0.0
Died of carcinoma	948	33.1
Died of other malignant tumor	14	0.5
Died of intercurrent disease	26	0.9
Cause of death unknown	3	0.1
Lost to follow-up	201	7.0
Total	2,866	

Table 4. 5-Year Survival by Stage, Treatment Started in 2008

FIGO Stage		Patients treated		5-year survival		Lost to follow-up
		No.		%		
I	A	451	1,225	95.5	90.5	103/1225(8.4%)
	B	18		76.5		
	C(b)	448		93.4		
	C(1)	24		72.9		
	C(2)	124		81.4		
	C(a)	160		79.4		
II	A	27	274	83.1	73.3	16/274(5.8%)
	B	32		65.1		
	C(b)	68		78.6		
	C(1)	12		50.0		
	C(2)	57		61.4		
	C(a)	78		82.0		
III	A	31	809	64.4	47.8	56/809(6.9%)
	B	109		56.6		
	C	669		45.5		
IV		234		30.2		9/234(3.8%)
Neoadjuvant Chemotherapy		321		35.9		17/321(5.3%)
Unknown		3		100.0		/3(0%)
Total		2,866				

**Table 5. 5-Year Survival by Stage, Treatment Started in 2008
(Surface Epithelial-Stromal Tumors)**

FIGO Stage		Patients treated		5-year survival		Lost to follow-up
		No.		%		
I	A	415	1,157	95.7	90.5	94/1157(8.1%)
	B	18		76.5		
	C(b)	430		93.7		
	C(1)	22		75.3		
	C(2)	118		81.3		
	C(a)	154		78.5		
II	A	27	257	83.1	73.5	14/257(5.4%)
	B	29		68.4		
	C(b)	62		78.1		
	C(1)	12		50.0		
	C(2)	54		61.1		
	C(a)	73		82.1		
III	A	30	766	63.2	48.1	54/766(7.0%)
	B	99		56.2		
	C	637		46.1		
IV		222		29.4		8/222(3.6%)
Neoadjuvant Chemotherapy		317		35.0		17/317(5.4%)
Unknown		3		100.0		0/3(0.0%)
Total		2,722				

Table 6. 5-Year Survival by Histological type, Treatment Started in 2008

Histological Type	FIGO Stage	Patients treated	5-year survival	Lost to follow-up
		No.	%	
Sex Cord/Stromal Tumors	I	6	100.0	2/6(33.3%)
	II	1	0.0	0/1(0.0%)
	III	2	50.0	1/2(50.0%)
	IV	0	—	—
	Neoadjuvant Chemotherapy	0	—	—
Germ Cell Tumors	I	54	93.9	5/54(9.3%)
	II	15	73.3	2/15(13.3%)
	III	28	53.6	0/28(0.0%)
	IV	7	71.4	0/7(0.0%)
	Neoadjuvant Chemotherapy	3	100.0	0/3(0.0%)


**Table 7. 5-Year Survival by Stage and Histological Type, Treatment Started in 2008
(Surface Epithelial-Stromal Tumors)**

FIGO Stage	Histology Type	Patients treated	5-year survival	Lost to follow-up
		No.	%	
I	Serous	154	92.1	17/154(11.0%)
	Mucinous	254	90.7	29/254(11.4%)
	Endometrioid	271	96.1	21/271(7.7%)
	Clear	411	86.5	25/411(6.1%)
	Other	67	87.9	2/67(3.0%)
II	Serous	72	63.9	4/72(5.6%)
	Mucinous	18	74.5	2/18(11.1%)
	Endometrioid	81	84.5	5/81(6.2%)
	Clear	47	66.7	0/47(0.0%)
	Other	39	76.5	3/39(7.7%)
III	Serous	443	49.9	23/443(5.2%)
	Mucinous	37	33.7	2/37(5.4%)
	Endometrioid	87	59.0	6/87(6.9%)
	Clear	110	33.4	8/110(7.3%)
	Other	89	53.3	15/89(16.9%)
IV	Serous	111	33.6	5/111(4.5%)
	Mucinous	21	41.9	0/21(0.0%)
	Endometrioid	27	30.8	0/27(0.0%)
	Clear	32	16.3	1/32(3.1%)
	Other	31	18.8	2/31(6.5%)
Neoadjuvant Chemotherapy	Serous	205	35.3	11/205(5.4%)
	Mucinous	9	28.6	0/9(0.0%)
	Endometrioid	23	42.4	1/23(4.3%)
	Clear	35	29.9	2/35(5.7%)
	Other	45	34.8	3/45(6.7%)
Unknown	Serous	1	100.0	0/1(0.0%)
	Mucinous	0	—	—
	Endometrioid	0	—	—
	Clear	2	100.0	0/2(0.0%)
	Other	0	—	—

**Table 8. 5-Year Survival by TNM Classification, Treatment Started in 2008
(Surface Epithelial-Stromal Tumors)**

TNM Stage			Patients treated		5-year survival	Lost to follow-up
			No.	%	%	
T1a	N0	M0	325	16.8	96.1	30/325(9.2%)
T1b	N0	M0	12	0.6	90.9	1/12(8.3%)
T1c	N0	M0	593	30.7	89.9	43/593(7.3%)
T2a	N0	M0	23	1.2	85.4	3/23(13.0%)
T2b	N0	M0	21	1.1	71.4	2/21(9.5%)
T2c	N0	M0	153	7.9	79.8	4/153(2.6%)
T3a	N0	M0	22	1.1	72.4	1/22(4.5%)
T3b	N0	M0	67	3.5	65.8	2/67(3.0%)
T3c	N0	M0	171	8.9	44.6	20/171(11.7%)
T1a	N1	M0	14	0.7	90.9	2/14(14.3%)
T1b	N1	M0	2	0.1	50.0	0/2(0.0%)
T1c	N1	M0	23	1.2	72.7	1/23(4.3%)
T2a	N1	M0	1	0.1	100.0	0/1(0.0%)
T2b	N1	M0	2	0.1	50.0	1/2(50.0%)
T2c	N1	M0	18	0.9	60.0	1/18(5.6%)
T3a	N1	M0	3	0.2	66.7	1/3(33.3%)
T3b	N1	M0	22	1.1	46.4	2/22(9.1%)
T3c	N1	M0	192	9.9	45.9	8/192(4.2%)
Any T	Any N	M1	266	13.8	31.2	11/266(4.1%)


Figure 1.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients by
FIGO Stage, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	665.2816	3	<.0001
Wilcoxon	638.7028	3	<.0001
-2Log (LR)	622.0156	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	226.6000	<.0001	<.0001
I	III	430.0000	<.0001	<.0001
I	IV	587.5000	<.0001	<.0001
II	III	165.1000	<.0001	<.0001
II	IV	116.5000	<.0001	<.0001
III	IV	37.2136	<.0001	<.0001


Figure 2.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients by
Histological Type, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	117.0450	4	<.0001
Wilcoxon	96.0807	4	<.0001
-2Log (LR)	124.3728	4	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Serous	Mucinous	76.2064	<.0001	<.0001
Serous	Endometrioid	97.0915	<.0001	<.0001
Serous	Clear	41.7037	<.0001	<.0001
Serous	Other	36.6190	<.0001	<.0001
Mucinous	Endometrioid	5.6462	0.0175	0.1218
Mucinous	Clear	1.8200	0.1773	0.6603
Mucinous	Other	20.1415	<.0001	<.0001
Endometrioid	Clear	10.7273	0.0011	0.0093
Endometrioid	Other	43.8377	<.0001	<.0001
Clear	Other	5.3004	0.0213	0.1440


Figure 3.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients by
FIGO Stage I Substage, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	16.3058	2	0.0003
Wilcoxon	19.3844	2	<.0001
-2Log (LR)	16.9070	2	0.0002

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
IA	IB	15.9665	<.0001	0.0002
IA	IC	12.4423	0.0004	0.0012
IB	IC	6.8664	0.0088	0.0239


Figure 4.
Kaplan-Meier Estimated Overall Survival Curves of Stage I Ovarian Cancer Patients by
Histological Type, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	17.6396	4	0.0015
Wilcoxon	16.9385	4	0.0020
-2Log (LR)	20.3625	4	0.0004

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Serous	Mucinos	0.0221	0.8819	0.9999
Serous	Endometrioid	6.5158	0.0107	0.0794
Serous	Clear	5.7442	0.0165	0.1161
Serous	Other	0.2741	0.6006	0.9850
Mucinos	Endometrioid	5.7886	0.0161	0.1136
Mucinos	Clear	4.0967	0.0430	0.2543
Mucinos	Other	0.0773	0.7810	0.9987
Endometrioid	Clear	16.7440	<.0001	0.0004
Endometrioid	Other	11.7035	0.0006	0.0056
Clear	Other	5.7253	0.0167	0.1172


Figure 5.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients by
FIGO Stage II Substage, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	2.7751	2	0.2497
Wilcoxon	2.1082	2	0.3485
-2Log (LR)	2.8038	2	0.2461

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
IIA	IIB	2.7419	0.0977	0.2224
IIA	IIC	0.1152	0.7343	0.9385
IIB	IIC	0.6626	0.4156	0.6943


Figure 6.
Kaplan-Meier Estimated Overall Survival Curves of Stage II Ovarian Cancer Patients by
Histological Type, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	6.2190	4	0.1834
Wilcoxon	6.5872	4	0.1594
-2Log (LR)	6.7710	4	0.1485

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Serous	Mucinous	1.9253	0.1653	0.6357
Serous	Endometrioid	5.4744	0.0193	0.1324
Serous	Clear	0.3107	0.5773	0.9810
Serous	Other	0.8859	0.3466	0.8808
Mucinous	Endometrioid	3.4860	0.0619	0.3352
Mucinous	Clear	0.6183	0.4317	0.9347
Mucinous	Other	0.1100	0.7401	0.9974
Endometrioid	Clear	4.2289	0.0397	0.2393
Endometrioid	Other	3.2849	0.0699	0.3662
Clear	Other	0.1574	0.6916	0.9948


Figure 7.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients by
FIGO Stage III Substage, IV Stage, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	42.7394	3	<.0001
Wilcoxon	56.5262	3	<.0001
-2Log (LR)	39.5341	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
IIIA	IIIB	0.4240	0.5149	0.9152
IIIA	IIIC	1.5635	0.2112	0.5947
IIIA	IV	39.6399	<.0001	<.0001
IIIB	IIIC	0.4175	0.5182	0.9169
IIIB	IV	32.1947	<.0001	<.0001
IIIC	IV	20.2239	<.0001	<.0001


Figure 8.
Kaplan-Meier Estimated Overall Survival Curves of Stage III, IV Ovarian Cancer Patients by
Histological Type, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	31.5218	4	<.0001
Wilcoxon	49.3173	4	<.0001
-2Log (LR)	27.9720	4	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
Histological Type	Histological Type		Raw	Tukey-Kramer
Serous	Mucinos	10.8881	0.0010	0.0086
Serous	Endometrioid	1.5273	0.2165	0.7303
Serous	Clear	18.7364	<.0001	0.0001
Serous	Other	5.0305	0.0249	0.1640
Mucinos	Endometrioid	6.5850	0.0103	0.0767
Mucinos	Clear	7.5978	0.0058	0.0462
Mucinos	Other	0.9653	0.3259	0.8633
Endometrioid	Clear	18.8119	<.0001	0.0001
Endometrioid	Other	1.8587	0.1728	0.6512
Clear	Other	9.5948	0.0020	0.0167


Figure 9.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients with Serous Adenocarcinoma by FIGO Stage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	106.2797	3	<.0001
Wilcoxon	108.8155	3	<.0001
-2Log (LR)	122.6713	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	33.2243	<.0001	<.0001
I	III	52.4234	<.0001	<.0001
I	IV	98.8437	<.0001	<.0001
II	III	17.7718	<.0001	0.0001
II	IV	29.2222	<.0001	<.0001
III	IV	0.3211	0.5709	0.9420


Figure 10.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients with Mucinous Adenocarcinoma by FIGO Stage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	114.5348	3	<.0001
Wilcoxon	120.0618	3	<.0001
-2Log (LR)	79.4646	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	48.3981	<.0001	<.0001
I	III	96.6977	<.0001	<.0001
I	IV	91.1791	<.0001	<.0001
II	III	35.6276	<.0001	<.0001
II	IV	13.1234	0.0003	0.0017
III	IV	9.4933	0.0021	0.0111


Figure 11.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients with Endometrioid Adenocarcinoma by FIGO Stage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	158.5680	3	<.0001
Wilcoxon	151.6319	3	<.0001
-2Log (LR)	115.7985	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	32.6664	<.0001	<.0001
I	III	88.2406	<.0001	<.0001
I	IV	121.3000	<.0001	<.0001
II	III	20.6835	<.0001	<.0001
II	IV	16.3195	<.0001	0.0003
III	IV	3.8753	0.0490	0.1999

Figure 12.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Cancer Patients with Clear Cell Adenocarcinoma by FIGO Stage, Treatment Started in 2008



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	251.0919	3	<.0001
Wilcoxon	245.0897	3	<.0001
-2Log (LR)	183.4215	3	<.0001

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	90.1977	<.0001	<.0001
I	III	179.1000	<.0001	<.0001
I	IV	212.1000	<.0001	<.0001
II	III	64.6938	<.0001	<.0001
II	IV	21.6650	<.0001	<.0001
III	IV	31.3859	<.0001	<.0001

卵巣境界悪性腫瘍治療成績

Statement for the Year 2008, Inclusive, Borderline Ovarian Tumor

Table A. 5-Year Results, Stage I-IV

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
○	010003 HOKKAIDO CANCER CENTER	1	0	1	0	0	0	0	0	0	0
○	010024 NTT EAST JAPAN SAPPORO HOSP.	2	0	2	0	0	0	0	0	0	0
○	010027 HOKKAIDO UNIV.	3	0	3	0	0	0	0	0	0	0
○	010028 KKR SAPPORO MED. CENTER	4	0	4	0	0	0	0	0	0	0
○	010038 ASAHIKAWA MED. UNIV.	5	0	1	0	0	0	0	0	0	4
○	010040 ASAHIKAWA MED. COLL.	7	0	7	0	0	0	0	0	0	0
○	020012 HIROSAKI UNIV.	2	0	2	0	0	0	0	0	0	0
	040004 TOHOKU UNIV.	13	0	9	0	0	0	0	0	0	4
	040008 MIYAGI CANCER CENTER	7	0	3	0	0	2	0	0	0	2
	040013 SENDAI MED. CENTER	4	0	0	0	0	0	0	0	0	4
○	050001 AKITA RED CROSS HOSP.	2	0	2	0	0	0	0	0	0	0
○	050003 AKITA UNIV.	4	0	4	0	0	0	0	0	0	0
	060002 YAMAGATA PREF. CENTRAL HOSP.	4	0	3	0	0	0	0	0	0	1
○	080001 TSUCHIURA KYODO GENERAL HOSP	1	0	0	0	0	1	0	0	0	0
○	080006 TSUKUBA GAKUEN HOSP.	1	0	1	0	0	0	0	0	0	0
○	080007 TSUKUBA UNIV.	19	0	14	1	0	1	0	0	0	3
	080021 HITACHI GENERAL HOSP.	6	6	0	0	0	0	0	0	0	0
○	080031 TSUKUBA MED. CENTER	1	0	1	0	0	0	0	0	0	0
○	090001 TOCHIGI MED. CENTER	1	0	1	0	0	0	0	0	0	0
○	090004 DOKKYO MED. UNIV.	5	0	5	0	0	0	0	0	0	0
	090005 SAISEIKAI UTSUNOMIYA HOSP.	1	0	0	0	0	0	0	0	0	1
	090011 ASHIKAGA RED CROSS HOSP.	2	0	1	0	0	0	0	0	0	1
○	090015 JICHI MED. UNIV.	10	0	10	0	0	0	0	0	0	0
	100012 GUNMA UNIV.	4	0	3	0	0	0	0	0	0	1
○	110008 SAITAMA MED. CENTER	6	0	6	0	0	0	0	0	0	0
○	110014 KOSHIGAYA MUNI HOSP.	7	0	5	0	0	1	0	0	0	1
○	110023 SAITAMA NATIONAL HOSP.	1	0	1	0	0	0	0	0	0	0
	110027 NATIONAL DEFENSE MED. COLL.	4	4	0	0	0	0	0	0	0	0
○	110030 SAITAMA CANCER CENTER	9	0	9	0	0	0	0	0	0	0
	110055 SAITAMA INTERNATIONAL MED. CENTER	13	0	8	0	0	0	0	0	0	5
○	120005 CHIBA UNIV.	9	0	9	0	0	0	0	0	0	0
	120009 NIPPON MED. SCH. CHIBA HOKUSOU HOSP.	4	4	0	0	0	0	0	0	0	0
○	120012 MATSUDO CITY HOSP.	1	0	1	0	0	0	0	0	0	0
	120015 TOKYO DENTAL COLL. ICHIKAWA GENERAL HOSP.	8	0	4	1	0	1	0	0	0	2
	120021 JIKEI UNIV. KASHIWA HOSP.	20	20	0	0	0	0	0	0	0	0
○	120023 JUNTENDO UNIV. URAYASU HOSP.	8	0	6	0	0	1	0	0	0	1
	120025 TOHO UNIV. SAKURA MED. CENTER	3	0	2	0	0	0	0	0	0	1
	120029 ASAHI CENTRAL HOSP.	7	7	0	0	0	0	0	0	0	0
	120035 KAMEDA MED. CENTER	14	0	11	0	0	0	0	0	0	3
○	130005 MITSUI MEMORIAL HOSP.	4	0	4	0	0	0	0	0	0	0
○	130009 NATIONAL CANCER CENTER	6	0	5	0	0	0	0	0	0	1
○	130013 JIKEI UNIV.	3	0	3	0	0	0	0	0	0	0
	130023 JUNTENDO UNIV.	14	0	7	1	0	0	0	0	0	6
	130024 TOKYO MED. DENT. UNIV.	1	1	0	0	0	0	0	0	0	0
○	130025 NIPPON MED. SCH.	1	0	1	0	0	0	0	0	0	0
○	130026 TOKYO UNIV.	10	0	9	0	0	1	0	0	0	0
○	130029 TOKYO WOMENS MED. UNIV. MED. CENTER EAST	5	0	5	0	0	0	0	0	0	0
	130034 JIKEI UNIV. KATSUSHIKA MED. CENTER	4	4	0	0	0	0	0	0	0	0
	130038 TOKYO METRO. BOKUTOH HOSP.	6	6	0	0	0	0	0	0	0	0
○	130044 NTT MED. CENTER TOKYO	5	0	3	0	0	0	1	0	0	1
	130046 SHOWA UNIV.	11	0	6	0	0	0	0	1	0	4
○	130050 TOHO UNIV. OMORI MED. CENTER	6	0	5	0	0	0	0	0	0	1

	A	B	C	D	E	F	G	H	I	J	K
	Institution	Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
○	130055 RED CROSS MED. CENTER	2	0	2	0	0	0	0	0	0	0
○	130061 TOKYO MED. CENTER	6	0	3	2	0	0	0	0	0	1
○	130063 KOSEI CENTRAL HOSP.	2	0	1	0	0	0	0	0	0	1
○	130064 TOHO UNIV. OHASHI MED. CENTER	2	0	1	0	0	0	0	0	0	1
○	130077 KEIO UNIV.	16	0	14	0	0	0	0	0	0	2
○	130080 NATIONAL CENTER FOR GLOBAL HEALTH AND MED.	2	2	0	0	0	0	0	0	0	0
○	130085 KOSEI HOSP.	1	1	0	0	0	0	0	0	0	0
○	130092 TEIKYO UNIV.	8	0	3	0	0	0	0	1	0	4
○	130095 NIHON UNIV.	6	0	6	0	0	0	0	0	0	0
○	130099 MUSASHINO RED CROSS HOSP.	13	0	13	0	0	0	0	0	0	0
○	130100 KYORIN UNIV.	3	0	2	0	0	1	0	0	0	0
○	130102 TOKYO METRO. TAMA MED. CENTER	3	0	3	0	0	0	0	0	0	0
○	130107 TACHIKAWA HOSP.	6	0	3	0	0	0	0	0	0	3
○	130112 MACHIDA MUNI. HOSP.	2	0	2	0	0	0	0	0	0	0
○	130119 NIPPON MED. SCH. TAMA NAGAYAMA HOSP.	3	3	0	0	0	0	0	0	0	0
○	130122 TOKYO METRO. KOMAGOME HOSP.	10	0	7	0	0	1	0	1	0	1
○	130124 KYOUDO HOSP.	1	0	1	0	0	0	0	0	0	0
○	130125 CANCER INST. HOSP.	15	0	15	0	0	0	0	0	0	0
○	130135 TAMA-NAMBU SHIKI HOSP.	7	7	0	0	0	0	0	0	0	0
○	130137 TOKAI UNIV. HACHIOJI HOSP.	1	1	0	0	0	0	0	0	0	0
○	140006 NIPPON MED. SCH. MUSASHI KOSUGI HOSP.	4	0	4	0	0	0	0	0	0	0
○	140012 ST. MARIANNA UNIV.	9	0	5	0	0	0	0	0	1	3
○	140017 SHOWA UNIV. FUJIGAOKA HOSP.	9	0	6	0	0	0	0	0	0	3
○	140020 KITASATO UNIV.	14	0	6	0	0	1	0	0	0	7
○	140029 YOKOHAMA CITY UNIV.	3	0	3	0	0	0	0	0	0	0
○	140030 YOKOHAMA MINAMI KYOSAI HOSP.	2	0	2	0	0	0	0	0	0	0
○	140035 YOKOHAMA MUNI. CITIZENS HOSP.	9	0	6	0	0	1	0	0	0	2
○	140037 ST. MARIANNA UNIV. YOKOHAMA CITY SEIBU HOSP.	4	0	2	0	0	0	0	0	0	2
○	140044 SHONAN KAMAKURA GENERAL HOSP.	3	0	2	0	0	1	0	0	0	0
○	140054 ISEHARA KYODO HOSP.	3	0	3	0	0	0	0	0	0	0
○	140055 TOKAI UNIV.	8	0	4	0	0	0	0	0	0	4
○	140059 KANAGAWA CANCER CENTER	4	0	4	0	0	0	0	0	0	0
○	140061 YOKOHAMA CITY UNIV. MED. CENTER	8	0	5	1	0	0	0	1	0	1
○	150002 YAMANASHI PREF. CENTRAL HOSP.	6	0	5	0	0	1	0	0	0	0
○	150006 UNIV. OF YAMANASHI	7	0	5	0	0	0	0	0	0	2
○	160001 NAGANO RED CROSS HOSP.	6	0	6	0	0	0	0	0	0	0
○	160022 NAGANO MUNI. HOSP.	2	0	2	0	0	0	0	0	0	0
○	170006 FUJI CITY GENERAL HOSP.	2	2	0	0	0	0	0	0	0	0
○	170009 SHIZUOKA RENERAL HOSP.	12	0	7	1	0	0	0	0	0	4
○	180010 NIIGATA CANCER CENTER HOSP.	4	0	4	0	0	0	0	0	0	0
○	190001 TOYAMA UNIV.	3	0	3	0	0	0	0	0	0	0
○	190002 TOYAMA RED CROSS HOSP.	3	0	1	0	0	0	0	0	0	2
○	190009 TAKAOKA CITY HOSP.	1	0	1	0	0	0	0	0	0	0
○	200001 KANAZAWA MED. UNIV.	1	0	1	0	0	0	0	0	0	0
○	200002 KANAZAWA MED. CENTER	1	0	1	0	0	0	0	0	0	0
○	200004 KANAZAWA UNIV.	6	0	6	0	0	0	0	0	0	0
○	210002 FUKUI PREF. HOSP.	4	0	2	0	0	0	0	0	0	2
○	220002 GIFU UNIV.	1	0	1	0	0	0	0	0	0	0
○	220006 OGAKI MUNI. HOSP.	4	0	3	0	0	0	0	0	0	1
○	230001 TOYOHASHI MUNI. HOSP.	11	0	8	0	0	0	0	0	0	3
○	230014 RED CROSS NAGOYA DAIICHI HOSP.	8	0	8	0	0	0	0	0	0	0
○	230031 NAGOYA UNIV.	3	3	0	0	0	0	0	0	0	0
○	230034 NAGOYA CITY UNIV.	5	0	4	0	0	0	0	0	1	0
○	230035 FUJITA HEALTH UNIV.	3	0	3	0	0	0	0	0	0	0
○	230040 AICHI MED. UNIV.	4	0	2	1	0	1	0	0	0	0
○	230052 AICHI CANCER CENTER	2	0	1	0	0	0	0	0	0	1
○	240002 MIE PREF. GENERAL MED. CENTER	2	0	1	0	0	0	0	0	0	1

A		B	C	D	E	F	G	H	I	J	K
Institution		Total No. Treated	no description	Alive with no Evidence of the Disease	Alive with Carcinoma	Alive with or without Carcinoma Unknown	Died of Carcinoma	Died of Other Malignant Tumor	Died of Intercurrent Disease	Cause of Death Unknown	Lost to follow-up
350003	TOKUYAMA CENTRAL HOSP.	4	4	0	0	0	0	0	0	0	0
350008	YAMAGUCHI RED CROSS HOSP.	3	0	1	0	0	0	0	0	0	2
350009	YAMAGUCHI UNIV.	5	0	1	0	0	0	0	0	0	4
360003	TOKUSHIMA UNIV.	4	0	0	0	0	1	0	0	0	3
370001	TAKAMATSU RED CROSS HOSP.	5	0	3	0	0	0	0	0	0	2
380001	SHIKOKU CANCER CENTER	5	0	3	0	0	0	0	0	0	2
380002	EHIME PREF. CENTRAL HOSP.	2	2	0	0	0	0	0	0	0	0
○ 380005	MATSUYAMA RED CROSS HOSP.	1	0	1	0	0	0	0	0	0	0
○ 380006	EHIME UNIV.	2	0	2	0	0	0	0	0	0	0
○ 390003	KOCHI HEALTH SCIENCE CENTER	2	0	2	0	0	0	0	0	0	0
○ 390006	KOCHI UNIV.	1	0	0	0	0	1	0	0	0	0
400008	UNIV. OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH	5	0	3	0	0	0	0	0	0	2
○ 400010	KYUSHU MED. CENTER	1	0	1	0	0	0	0	0	0	0
○ 400012	KYUSHU UNIV.	14	0	14	0	0	0	0	0	0	0
○ 400013	FUKUOKA UNIV.	11	0	10	1	0	0	0	0	0	0
400014	FUKUOKA RED CROSS HOSP.	5	0	2	0	0	0	0	0	0	3
400017	IIZUKA HOSP.	9	0	4	0	0	0	0	0	0	5
400020	KURUME UNIV.	1	0	0	0	0	0	0	0	0	1
400026	SAISEIKAI FUKUOKA GENERAL HOSP.	13	0	7	1	0	0	0	0	0	5
○ 400040	KYUSHU CANCER CENTER	3	0	2	0	0	0	0	1	0	0
410005	SAGA UNIV.	4	0	2	0	0	0	1	0	0	1
○ 420001	NAGASAKI HARBOR MED. CENTER CITY HOSP.	5	0	5	0	0	0	0	0	0	0
420002	NAGASAKI UNIV.	7	0	4	0	0	0	0	0	0	3
○ 420003	RED CROSS NAGASAKI ATOMIC BOMB HOSP.	1	0	0	0	0	1	0	0	0	0
420006	SASEBO KYOSAI HOSP.	2	0	1	0	0	0	0	0	0	1
430001	KUMAMOTO MED. CENTER	2	0	0	0	0	0	0	0	0	2
430002	KUMAMOTO UNIV.	14	0	11	0	0	0	0	0	0	3
430003	KUMAMOTO CITY HOSP.	6	0	4	0	0	0	0	0	0	2
440002	OITA PREF. HOSP.	3	0	1	0	0	0	0	0	0	2
440003	BEPPU MED. CENTER	5	5	0	0	0	0	0	0	0	0
440005	OITA UNIV.	4	0	3	0	0	0	0	0	0	1
○ 450001	MIYAZAKI PREF. HOSP.	9	0	8	0	0	0	0	0	0	1
○ 450005	MIYAZAKI UNIV.	8	1	3	0	0	4	0	0	0	0
460001	KAGOSHIMA UNIV.	11	11	0	0	0	0	0	0	0	0
460004	KAGOSHIMA CITY HOSP.	9	0	2	0	0	1	0	0	0	6
○ 470008	RYUKYU UNIV.	10	0	6	0	0	1	1	1	0	1
470010	OKINAWA PREF. CHUBU HOSP.	4	0	3	0	0	0	0	0	0	1
Total		1,086	120	682	13	0	28	4	7	2	230

Table 1. No. of Patients by Stage and Age

FIGO Stage		Age		~19		20~29		30~39		40~49		50~59		60~69		70~79		80~		Total		
		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	
I	A	7	1.4	33	6.6	54	10.8	55	11.0	69	13.8	53	10.6	39	7.8	9	1.8	319	63.9			
	B	0	0.0	0	0.0	0	0.0	1	0.2	6	1.2	0	0.0	2	0.4	0	0.0	9	1.8			
	C(b)	5	1.0	15	3.0	15	3.0	17	3.4	13	2.6	12	2.4	5	1.0	0	0.0	82	16.4			
	C(1)	0	0.0	0	0.0	1	0.2	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	3	0.6			
	C(2)	0	0.0	3	0.6	1	0.2	1	0.2	0	0.0	1	0.2	1	0.2	0	0.0	7	1.4			
	C(a)	2	0.4	5	1.0	8	1.6	6	1.2	5	1.0	7	1.4	3	0.6	2	0.4	38	7.6			
	total	14	2.8	56	11.2	79	15.8	81	16.2	94	18.8	73	14.6	50	10.0	11	2.2	458	91.8			
II	A	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2			
	B	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0			
	C(b)	0	0.0	0	0.0	0	0.0	0	0.0	2	0.4	0	0.0	1	0.2	0	0.0	3	0.6			
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	1	0.2	2	0.4			
	C(2)	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2	2	0.4	0	0.0	0	0.0	4	0.8			
	C(a)	0	0.0	0	0.0	1	0.2	0	0.0	4	0.8	0	0.0	2	0.4	0	0.0	7	1.4			
	total	0	0.0	0	0.0	1	0.2	2	0.4	8	1.6	2	0.4	3	0.6	1	0.2	17	3.4			
III	A	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	1	0.2	2	0.4			
	B	0	0.0	1	0.2	2	0.4	0	0.0	4	0.8	1	0.2	1	0.2	0	0.0	9	1.8			
	C	1	0.2	0	0.0	1	0.2	3	0.6	2	0.4	2	0.4	0	0.0	0	0.0	9	1.8			
	total	1	0.2	1	0.2	3	0.6	4	0.8	6	1.2	3	0.6	1	0.2	1	0.2	20	4.0			
IV	0	0.0	2	0.4	0	0.0	0	0.0	1	0.2	1	0.2	0	0.0	0	0.0	4	0.8				
Neoadjuvant Chemotherapy	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
Unknown	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0		
Total	15	3.0	59	11.8	83	16.6	87	17.4	109	21.8	79	15.8	54	10.8	13	2.6	499					

Table 2. No. of Patients by Histological Type

Histological Type		Surface Epithelial/Stromal Tumors															Sex Cord/Stromal Tumor				
		Serous		Mucinous		Others										Granulosa		Sertoli-Stromal (Intermediate)			
						Endometrioid		Clear		Proliferative Brenner		Mixed		Unclassified						Other	
FIGO Stage		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
I	A	66	13.2	177	35.5	6	1.2	2	0.4	2	0.4	9	1.8	0	0.0	1	0.2	32	6.4	2	0.4
	B	3	0.6	5	1.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
	C(b)	15	3.0	43	8.6	3	0.6	3	0.6	0	0.0	4	0.8	0	0.0	0	0.0	7	1.4	0	0.0
	C(1)	1	0.2	0	0.0	0	0.0	1	0.2	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
	C(2)	4	0.8	2	0.4	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(a)	3	0.6	22	4.4	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	1	0.2	6	1.2	0	0.0
	total	92	18.4	249	49.9	10	2.0	7	1.4	2	0.4	15	3.0	0	0.0	2	0.4	45	9.0	2	0.4
II	A	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	B	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(b)	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	1	0.2	0	0.0
	C(1)	2	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(2)	3	0.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(a)	3	0.6	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.4	0	0.0
	total	9	1.8	1	0.2	2	0.4	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	3	0.6	0	0.0
III	A	2	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	B	4	0.8	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	2	0.4	0	0.0
	C	6	1.2	1	0.2	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0
	total	12	2.4	2	0.4	1	0.2	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	3	0.6	0	0.0
IV		3	0.6	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Neoadjuvant Chemotherapy	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Total	116	23.2	253	50.7	13	2.6	7	1.4	2	0.4	16	3.2	1	0.2	2	0.4	51	10.2	2	0.4

Histological Type		Sex Cord/Stromal Tumor						Germ cell Tumors						Others						Total			
		Gynadrioblastoma		Steroid		Others		Immature teratoma (G1,G2)		Others				Gonadoblastoma		Mixed Germ Cell-Sex Cord/Stromal		Other					
										Carcinoid		Neuroectodermal										Other	
FIGO Stage		No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
I	A	0	0.0	2	0.4	0	0.0	16	3.2	3	0.6	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	319	63.9
	B	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	9	1.8
	C(b)	0	0.0	1	0.2	0	0.0	5	1.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	82	16.4
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.6
	C(2)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	7	1.4
	C(a)	1	0.2	0	0.0	0	0.0	4	0.8	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	38	7.6
	total	1	0.2	3	0.6	0	0.0	25	5.0	4	0.8	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	458	91.8
II	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2
	B	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	C(b)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	0.6
	C(1)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.4
	C(2)	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	0.8
	C(a)	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	7	1.4
	total	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	17	3.4
III	A	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	2	0.4
	B	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	9	1.8
	C	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	9	1.8
	total	0	0.0	0	0.0	0	0.0	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	20	4.0
IV		0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	0.8
	Neoadjuvant Chemotherapy	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Unknown	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
	Total	1	0.2	3	0.6	0	0.0	26	5.2	5	1.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.2	499	

Table 3. 5-Year Results, Treatment Started in 2008

5-year result	No. of patients	%
Alive with no Evidence of the Disease	441	88.4
Alive with Carcinoma	7	1.4
Alive with or without Carcinoma Unknown	0	0.0
Died of Carcinoma	18	3.6
Died of Other Malignant Tumor	2	0.4
Died of Intercurrent Disease	5	1.0
Cause of Death Unknown	1	0.2
Lost to follow-up	25	5.0
Total	499	

Table 4. 5-Year Survival by Stage, Treatment Started in 2008

FIGO Stage		Patients treated		5-year survival		Lost to follow-up
		No.		%		
I	A	319	458	95.9	96.3	23/458(5.0%)
	B	9		100.0		
	C(b)	82		100.0		
	C(1)	3		100.0		
	C(2)	7		100.0		
	C(a)	38		89.1		
II	A	1	17	100.0	100.0	1/17(5.9%)
	B	0		—		
	C(b)	3		100.0		
	C(1)	2		100.0		
	C(2)	4		100.0		
III	A	2	20	100.0	68.6	1/20(5.0%)
	B	9		66.7		
	C	9		66.7		
IV		4		0.0		0/4(0.0%)
Neoadjuvant Chemotherapy		0		—		—
Unknown		0		—		—
Total		499				

**Table 5. 5-Year Survival by Stage, Treatment Started in 2008
(Surface Epithelial-Stromal Tumors)**

FIGO Stage		Patients treated		5-year survival		Lost to follow-up
		No.		%		
I	A	263	377	95.4	95.7	22/377(5.8%)
	B	9		100.0		
	C(b)	68		100.0		
	C(1)	3		100.0		
	C(2)	7		100.0		
	C(a)	27		84.5		
II	A	1	13	100.0	100.0	1/13(7.7%)
	B	0		—		
	C(b)	2		100.0		
	C(1)	2		100.0		
	C(2)	3		100.0		
III	A	2	16	100.0	80.0	1/16(6.3%)
	B	6		83.3		
	C	8		75.0		
IV		4		0.0		0/4(0.0%)
Neoadjuvant Chemotherapy		0		—		—
Unknown		0		—		—
Total		410				


Table 6. 5-Year Survival by Histological Type, Treatment Started in 2008

Histological Type	FIGO Stage	Patients treated	5-year survival	Lost to follow-up
		No.	%	
Sex Cord/Stromal Tumors	I	51	98.0	1/51(2.0%)
	II	3	100.0	0/3(0.0%)
	III	3	33.3	0/3(0.0%)
	IV	0	—	—
	Neoadjuvant Chemotherapy	0	—	—
Germ Cell Tumors	I	29	100.0	0/29(0.0%)
	II	1	100.0	0/1(0.0%)
	III	1	0.0	0/1(0.0%)
	IV	0	—	—
	Neoadjuvant Chemotherapy	0	—	—

Table 7. 5-Year Survival by Stage and Histological Type, Treatment Started in 2008

FIGO Stage	Histology Type	Patients treated	5-year survival	Lost to follow-up
		No.	%	
I	Serous	92	96.3	7/92(7.6%)
	Mucinous	249	96.6	11/249(4.4%)
	Endometrioid	10	100.0	1/10(10.0%)
	Clear	7	83.3	0/7(0.0%)
	Other	19	82.6	3/19(15.8%)
II	Serous	9	100.0	0/9(0.0%)
	Mucinous	1	100.0	0/1(0.0%)
	Endometrioid	2	100.0	0/2(0.0%)
	Clear	0	—	—
	Other	1	100.0	1/1(100.0%)
III	Serous	12	72.7	1/12(8.3%)
	Mucinous	2	100.0	0/2(0.0%)
	Endometrioid	1	100.0	0/1(0.0%)
	Clear	0	—	—
	Other	1	100.0	0/1(0.0%)
IV	Serous	3	0.0	0/3(0.0%)
	Mucinous	1	0.0	0/1(0.0%)
	Endometrioid	0	—	—
	Clear	0	—	—
	Other	0	—	—
Neoadjuvant Chemotherapy	Serous	0	—	—
	Mucinous	0	—	—
	Endometrioid	0	—	—
	Clear	0	—	—
	Other	0	—	—
Unknown	Serous	0	—	—
	Mucinous	0	—	—
	Endometrioid	0	—	—
	Clear	0	—	—
	Other	0	—	—

Figure 1.
Kaplan-Meier Estimated Overall Survival Curves of Ovarian Borderline Tumor Patients by FIGO Stage, Treatment Started in 2008 (Surface Epithelial-Stromal Tumors)



Test of Equality over Strata			
Test	Chi-Square	DF	Pr>Chi-Square
Log-rank	45.9928	3	<.0001
Wilcoxon	38.8287	3	<.0001
-2Log(LR)	14.5602	3	0.0022

Adjustment for Multiple Comparisons for the Log-rank Test				
Strata Comparison		Chi-Square	p-Values	
FIGO Stage	FIGO Stage		Raw	Tukey-Kramer
I	II	2.1287	0.1446	0.4625
I	III	8.3930	0.0038	0.0197
I	IV	16.2130	<.0001	0.0003
II	III	5.5595	0.0184	0.0854
II	IV	8.7634	0.0031	0.0162
III	IV	0.0943	0.7587	0.9900